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5ABBREVIATIONS
1 ABBREVIATIONS
COX cyclooxygenase
CT computed tomography
EG esophagogastric
EN4 endothelium-specific antibody (anti-CD31)
EUR euro
EUS endoscopic ultrasonography
FCR Finnish Cancer Registry
FGF fibroblast growth factor
GERD gastroesophageal reflux disease
GSH glutathione
HGD high-grade dysplasia
HRP horse-radish peroxidase
ICDO International Classification of Diseases for Oncology
LES lower esophageal sphincter
M mucosa
MMP matrix metalloproteinase
MP myeloperoxidase
Nd:YAG neodymium: yttrium-aluminum-garnet
NOS nitric oxide synthase
PAL-E endothelium-specific antibody (recognizes an undefined
endothelium-specific antigen)
PBS phosphate-buffered saline
PET positron emission tomography
SD standard deviation
SEM standard error of mean
SEMS self-expanding metallic stent
SM submucosa
SMA smooth muscle cell actin
SOD superoxide dismutase
TGF transforming growth factor
TLC thin-layer chromatography
TNM tumor node metastase
UICC Union International Contre le Cancer
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
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3 ABSTRACT
BACKGROUND
One of the most lethal malignancies, with less than 5% of patients
surviving in the long term, has been adenocarcinoma near the
esophagogastric (EG) junction. Esophageal adenocarcinoma is a
complication of gastroesophageal reflux disease (GERD) and arises
from Barrett’s mucosa. Although the esophagitis-metaplasia-dysplasia-
adenocarcinoma sequence in Barrett’s mucosa is well recognized, the
pathomechanism in this malignant transformations is not well defined.
The aim of the present study was to evaluate 1) changes in the
incidence of adenocarcinoma of the esophagus and gastric cardia in
Finland, 2) the role of oxidative stress and radical scavenger capacity in
the pathogenesis and malignant transformation of Barrett’s esophagus,
3) the extent of angiogenesis and lymphangiogenesis in Barrett’s
esophagus and related malignancies, 4) the fate of patients with
adenocarcinoma near the EG junction, and to compare 5) the results
of different types of therapeutic procedures in the treatment of these
adenocarcinomas.
PATIENTS AND METHODS
The Finnish Cancer Registry provided the primary data for Studies I
and IV. In Study I, the trends in adenocarcinoma of the esophagus and
gastric cardia were evaluated in Finland during the 20-year period of
1976 to 1995; in Study IV, the outcome of all 402 patients treated
between 1990 and 1998 in two Finnish health-care districts with a
population of 1 750 000 was analyzed.
In Study II, parameters of oxidative metabolism (myeloperoxidase,
MP; glutathione, GSH; superoxide dismutase, SOD), and DNA adducts
were measured to discover the role of oxidative stress and radical
scavenger capacity in the pathogenesis and malignant transformation
of Barrett’s esophagus. Mucosal specimens were taken from 52 patients
in six groups: symptomatic GERD without and with endoscopic
esophagitis, Barrett’s metaplastic epithelium without dysplasia,
Barrett’s epithelium with dysplasia, adenocarcinoma in the esophagus/
esophagogastric junction, and control group.
For Study III, an immunohistochemical whole-mount section
technique was set up to show expression of well-established angiogenic
8 ABSTRACT
molecules during development of Barrett’s adenocarcinoma. Mucosa
samples were collected from 15 surgically resected dysplasia and
carcinoma patients.
In Study V, the relative lifetime costs and clinical results of the
Nd:YAG laser were compared to those of self-expanding metallic
stents (SEMS) as alternative forms of primary palliation of dysphagia
for adenocarcinoma near the EG junction. In this retrospective analysis,
32 patients had been treated with laser therapy and 20 with SEMS.
RESULTS
The incidence of esophageal adenocarcinoma increased significantly
in Finland only in men (almost 300%). In neither sex did the incidence
of the cancer of gastric cardia change. The combined incidence rate of
these adenocarcinomas in men increased steadily, but this increase
was not as dramatic as in esophageal adenocarcinoma.
The esophagitis-metaplasia-dysplasia-adenocarcinoma sequence
of Barrett’s esophagus revealed simultaneous formation of DNA
adducts, increased oxidative stress (increased MP activity), and
decreased antioxidant capacity (decreased GSH content). This sequence
was also characterized by on increasing percentage of immature blood
vessels. Barrett’s esophagus was already strongly neovascularized. This
metaplastic epithelium expressed high levels of vascular endothelial
growth factor A and its receptor. Matrix metalloproteinases were also
expressed along the lining of the new blood vessels. In addition, we
showed 3-dimensional evidence that the rich new vascular bed is
already highly abnormal in non-malignant Barrett’s epithelium and in
adenocarcinoma; the structure of lymphatics was loose in dysplasia and
cancer. Furthermore, adenocarcinoma overexpressed lymphangiogenic
growth factor and its receptor.
Overall, prognosis of these patients was still poor, with only 12.5%
surviving more than 5 years. Surgical resection offered the best chance
for a cure with a 5-year survival rate of 29.0%. Less than one percent of
the patients treated with other methods were alive at 5 years. On the
other hand, half the adenocarcinoma patients who were eligible for
major surgery with 2-field lymphadenectomy had a chance to survive
in the long term (50% 5-year survival). Laser therapy palliated dysphagia
effectively with lower morbidity and mortality rates than did the use of
self-expanding metallic stents, and without increased costs or hospital
stays.
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CONCLUSION
Though the increase in incidence of esophageal adenocarcinoma in
Finnish men has seemed highly significant, the combined incidence of
cancers of the EG junction shows only a slight increase, comparable to
that of other cancers which are increasing.
Simultaneous formation of DNA adducts, increased oxidative stress,
and decreased antioxidant capacity indicates the important role of
oxidative stress in the pathogenesis and malignant transformation of
Barrett’s epithelium. In early stages of this process, the angioarchitecture
is already abnormal. High expression of vascular endothelial growth
factor and its receptor, and of matrix metalloproteinases suggests their
important role in angiogenesis in Barrett’s epithelium and related
adenocarcinoma. In addition, tumor lymphangiogenesis may be an
important phenomenon for the frequent lymph node metastasis
formation found in esophageal adenocarcinoma.
Although overall prognosis for adenocarcinoma near the EG
junction is poor, a substantial percentage of patients eligible for major
surgery achieve long-term survival. In palliation, laser therapy relieves
dysphagia of these patients effectively without increased costs or
hospital stays and with lower morbidity and mortality rates than for
self-expanding metallic stents.
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4 INTRODUCTION
In several countries, the incidence of adenocarcinoma in the esophagus
and gastric cardia, especially in men, has increased (Powell and
McConkey 1990, Blot et al. 1991, Hansson et al. 1993, Hansen et al.
1997, Lord et al. 1998). The rate of increase in the USA has surpassed
that of any other cancer type (Blot et al. 1991). The reason for this
increase is unknown. Problems in the classification and coding of the
primary site create difficulties in the analysis of the occurrence of
cancers located near the esophagogastric junction. In addition, the
definition of gastric cardia in the literature is inconsistent (Appelman
1998, Spechler 2001). The gradual transfer of the name “cancer of
gastric cardia” to “esophageal adenocarcinoma” in coding may
therefore explain these rising incidence rates for esophageal
adenocarcinoma (Hansen et al. 1997).
A strong epidemiological association exists between esophageal
adenocarcinoma and gastroesophageal reflux disease (Lagergren et al.
1999a). A complication of gastroesophageal reflux disease is Barrett’s
esophagus, the most important risk factor for esophageal adeno-
carcinoma. Though the high risk for esophageal adenocarcinoma
associated with this specialized intestinal metaplasia has recently been
questioned, the risk may be up 30 to 125 times as great as in the
general population (Cameron et al. 1985, Hameeteman et al. 1989).
The presence of dysplasia, especially high-grade dysplasia (HGD),
length, large hiatal hernia, and the presence of Barrett’s ulcer are
features which have predicted the development of adenocarcinoma in
Barrett’s epithelium (Iftikhar et al. 1992, Dees et al. 1996, Weston et
al. 1999). Although the major factor contributing to this metaplasia
seems to be the synergistic action of acid, pepsin, and duodeno-
gastoesophaeal reflux, and a direct morphological sequence from
metaplasia via dysplasia to adenocarcinoma is recognizable, the exact
pathomechanism of this malignant transformation is unknown
(Hameeteman et al. 1989, Vaezi and Richter 1996, Öberg et al. 2000).
Cancer in several organs has been linked to chronic inflammation
and oxygen free radicals (Shimoda et al. 1994, Holzinger et al. 1999).
Recently, antioxidants have been inversely associated with risk for
esophageal adenocarcinoma (Terry et al. 2000). In esophagitis and
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Barrett’s epithelium, because growing evidence exists that oxidative
stress is involved in the pathogenesis of mucosal damage (Olyaee et al.
1995, Wetcher et al. 1995, Oh et al. 2001), the malignant trans-
formation of Barrett’s esophagus may thus be related to free radicals
and oxidative stress.
Precancerous tissue on its way to becoming cancerous is required
to have angiogenic capacity. This angiogenesis is often activated, as
seen also in Barrett’s esophagus, during the early stages in tumor
development (Hanahan and Folkman 1996, Couvelard et al. 2000). In
Barrett’s epithelium, the morphology of this neovascularization is not
characterized, nor is any possible role evident for lymphangiogenesis in
the early lymphatic spread of these tumors.
Adenocarcinoma near the esophagogastric junction is one of the
most lethal malignancies known. In two population-based studies
before the 1980’s, the overall 5-year survival was 2.7% for lesions at the
esophagus and 3.7% at the esophagogastric junction (Allum et al.
1986, Matthews and Walker 1990). Though in recent surgical series
the 5-year survival rate has been over 30%, these are highly selected
and do not reflect the overall pattern of this disease at population level
(Siewert et al. 2000, Collard 2001, Hagen et al. 2001). In this era of
continuous development in treatment modalities, a detailed picture of
the nature and behavior of this tumor under modern staging and
treatment modalities is lacking.
Endoscopic treatment modalities such as stents or laser therapy
play an important role in palliation of these patients, but continuous
debate in the literature confirms that none of the palliative methods to
treat esophageal cancer is entirely optimal. Obstructive carcinomas of
the EG junction are especially difficult to palliate. Despite the different
needs for repeated therapy and different one-off costs between palliative
treatment modalities, the economic implications of the treatment of
dysphagia due to malignant disease, especially adenocarcinoma near
the EG junction, have received little attention. In this era of increasing
interest in the health resources consumed, selection of treatment
should take into account the cost of therapy.
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5.1 Gross anatomy and lymphatic spread of adenocarcinoma
in the distal esophagus and esophagogastric junction
Esophageal adenocarcinoma is seldom located above the tracheal
bifurcation, 24 to 26 cm from the incisor teeth (Hagen and DeMeester
2000). Below this level, the esophagus lies between the pericardium,
aorta, and vertebral column. Laterally it is covered by the hilar structures
of the lungs, mediastinal pleura, and pulmonary ligaments. In the
lower mediastinum the esophagus passes beside the azygos vein and
thoracic duct, and together with the vagal nerves it reaches the
diaphragmatic hiatus. The length of the abdominal esophagus is
variable, generally a few centimeters, meaning that the esophagogastic
junction lies just below the diaphragm (Skandalakis and Ellis 2000).
The abdominal esophagus and EG junction are located retroperitoneally
on top of the aorta and left diaphragmatic crus. The peritoneum and
left lobe of the liver cover them anteriorly.
Though reflecting the person’s height, 38 to 40 cm from the
incisors lies the squamo-columnar junction. Below this junction, cardiac
mucosa, based on recent studies, rarely extends more than a few
millimeters (Kilgore et al. 2000, Chandrasoma et al. 2000); even in
normal people, the presence of cardiac mucosa, with its tubular
glands lined almost exclusively with mucin-secreting cells (Owen 1986,
Spechler 2001), has been questioned, as well (Chandrasoma et al.
2000, DeMeester 2001).
The lymphatics of the esophagus originate from the deepest part
of the mucosa (Liebermann-Meffert 2001). In the submucosa they
form plexuses and longitudinal collecting channels. Though the lymph
flow in these channels is directed by valves, the direction of flow,
especially in cancer with obstructions of the lymphatics, is unpredictable
(Liebermann-Meffert 2001). Tumor cells may travel a considerable
distance before reaching the lymph nodes. Figure 1 outlines the
lymphatic drainage of the EG junctional area.
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FIGURE 1 Lymphatic drainage of the EG junctional area
Adenocarcinoma near the EG junction spreads early into lymphatic
tissue. One-fifth of the patients with disease limited to the submucosa
and over 80% of transmural tumors have nodal metastases (Rice et al.
1998, Stein et al. 2000a, Hagen et al. 2001). Most frequently, these
metastases are located in the paratumoral lymph nodes (Nigro et al.
1999a, Van de Ven et al. 1999). Regardless of their location, these
tumors frequently have lymphatic metastases on either side of the
diaphragm (Nigro et al. 1999a, Van de Ven et al. 1999). Up to 35% of
patients having adenocarcinoma at the distal esophagus and 20% of
those with cancer at the EG junction may have cervical nodal metastases,
sometimes even without thoracic nodal involvement (Altorki and Skinner
1997, Van de Ven et al. 1999). In most cases, these are probably
patients with advanced disease showing a wide lymphatic spread
(Sons and Borchard 1986).
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5.2 Classification of adenocarcinoma near the
esophagogastric junction
The classification of adenocarcinoma near the EG junction is still
controversial, mainly because the definition of gastric cardia in the
literature is inconsistent (Appelman 1998, Spechler 2001). The
International Union Against Cancer (UICC) even classifies cancer of
the cardia as a subgroup of gastric cancer without a specific definition
(International Classification of Diseases for Oncology [ICDO] site
code C16.0) (UICC 1997). Data reported in the literature about
cancer of gastric cardia and esophageal adenocarcinoma are thus not
always comparable.
In order to overcome the difficulties in classification of these
cancers, Siewert et al (1987) proposed an anatomical-topographical
classification based upon the location of the tumor center 5 cm
proximal or distal to the lower esophageal sphincter (Figure 2). Type I
adenocarcinoma includes the tumors of the distal esophagus. The
center or more than two-thirds of the tumor is located more than 1 cm
above the EG junction (a). A Type II tumor is located between 1 cm
above and 2 cm below the EG junction (b). Carcinoma of Type III
represents a carcinoma of the proximal stomach, and the main tumor
center is located between 2 and 5 cm below the EG junction (c).
Although this classification has been accepted in a recent consensus
conference organized by the International Gastric Cancer Association
and the International Society for Diseases of the Esophagus, it is not
based on histology (Siewert and Bumm 1997).
5.3 Epidemiology
Adenocarcinoma located either in the distal esophagus or gastric
cardia mainly occurs in patients over 50 years of age. The mean age at
diagnosis has been around 67 (Dolan et al. 1999). The incidence is
several times more common in males and higher among whites than
blacks (Yang and Davis 1988, Blot et al. 1991).
In several countries, the incidence of adenocarcinoma in the
esophagus, especially in men, has increased (Table 1) (Powell and
McConkey 1990, Blot et al. 1991, Hansson et al. 1993, Hansen et al.
1997, Lord et al. 1998). Before the mid-1970’s, adenocarcinoma
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accounted for less than 5% of all esophageal cancers (Turnbull and
Goodner 1968, Webb and Busuttil 1978), but by the 1990’s this
number had increased to more than 25% in men in various countries
(Blot et al. 1991, Hansson et al. 1993, Hansen et al. 1997, Lord et al.
1998). In the USA, the rate of increase has surpassed that of any other
cancer type (Blot et al. 1991). At the same time, the incidence of
cancer of the gastric cardia in both sexes and the incidence of esophageal
adenocarcinoma in women have remained relatively stable in several
other countries (Levi et al. 1990, Levi 1991, Blot et al. 1991, Hansson
et al. 1993, McKinney et al. 1995, Armstrong and Borman 1996,
Hansen et al. 1997, Lord et al. 1998). In some countries, cancer of the
gastric cardia and esophageal adenocarcinoma in women are also on
the increase (Blot et al. 1991, Dolan et al. 1999). The combined
FIGURE 2 Classification of adenocarcinomas near the EG junction by Siewert
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TABLE 1 Change in incidence of esophageal and gastric cardial adenocarcinoma
Author Location Data – Esophageal Cancer of Esophagus
and year collection adeno- gastric and cardia
period carcinoma* cardia* combined*
Male Female Male Female Male Female
Hansen Norway 1958–1962 0.1 0.0 3.5 1.3 3.6 1.3
et al. 1997 1988–1992 0.8 0.1 3.1 0.9 3.9 1.0
Powell and United 1962–1966 0.2 0.1 1.1 0.4 1.3 0.5
McConkey Kingdom 1977–1981 0.9 0.3 3.0 1.0 3.9 1.3
1990
Blot et al. USA 1976 0.9 0.15 2.4 0.4 3.3 0.55
1991 1987 1.9 0.2 3.4 0.6 5.3 0.8
Levi et al. Switzerland 1976–1981 0.4 0.2 6.5 1.1 6.9 1.3
1990 and 1982–1987 1.6 0.1 5.3 0.8 6.9 0.9
Levi 1991
Armstrong New 1978–1982 1.8 0.3 2.2 0.5 4.0 0.8
and Zealand 1988–1992 2.3 0.5 1.9 0.4 4.2 0.9
Borman
1996
Lord et al. Australia 1982 0.8 0.16 2.6 0.5 3.4 0.56
1998 1992 2.3 0.3 3.0 0.6 5.3 0.9
*Annual age adjusted incidence per 100 000 population
incidence of these cancers often shrinks the substantial rise (up to 300-
700%) in the incidence of esophageal adenocarcinoma, reducing it to
nearly non-existent (Levi et al. 1990, Levi 1991, Armstrong and Borman
1996, Hansen et al. 1997), or to a more reasonable increase, 50 to
60% (Blot et al.1991, Lord et al. 1998).
5.4 Risk factors for adenocarcinoma of the esophagus
and cardia
A strong correlation exists between GERD and esophageal adeno-
carcinoma, and an association has also been found between GERD and
cancer of the gastric cardia (Lagergren et al. 1999a). The most important
risk factor for esophageal adenocarcinoma is, however, Barrett’s
esophagus. With long (>3 cm) segments of Barrett’s epithelium, the risk
of developing an adenocarcinoma has been estimated to be 30 to 125
times as high as in the normal population (Cameron et al. 1985,
Hameeteman et al. 1989). Recently, this high cancer risk has been
considered to be a publication bias; the newest, more reliable estimation
of cancer risk in non-dysplastic Barrett’s mucosa is 0.5% per year, which
Discussion
The main aim of treatment for a patient with advanced adenocarcinoma
of the oesophagus or GE junction is palliation of dysphagia, and our
study shows that this aim could be achieved as effectively with placement
of self-expandable metallic stents as with laser therapy, without differences
in overall cost of treatment. No significant difference existed in this
retrospective study in overall survival or in patient demographics between
those with laser therapy and with SEMS (Table 1 and 3).
No prospective randomised studies compare laser therapy and
SEMS in the treatment of malignant dysphagia purely due to carcinomas
of the GE junction. Regarding more proximal location, one prospective
randomised trial showed SEMS to offer better palliation of dysphagia
than did laser therapy14. However, over 40% of the tumours involved
were located in the middle or upper oesophagus14. One critical review
of reports published on SEMS for palliation of stenosing tumours of
the oesophagus observed a high rate of early and late complications
such as stent migration, incomplete expansion, and tumour ingrowth15.
SEMS have been proven superior to oesophageal intubation with
plastic prostheses7-9. Similarly, laser therapy has provided better
TABLE 4. Complications by group.
Treatment modality Laser Stent
No. of patients (%) (n=32) (n=20)
Early complication 2 (6.3) 6 (30)
Perforation 2 (6.3) 0
Bleeding 0 3 (15)
Infection 0 2 (10)
Malpositioning - 2 (10)
Late complication 13 (40.6) 6 (30)
Obstruction* 12 (38) 5 (25)
Stent migration 1 (3.1) 1 (5)
Tumour overgrowth 0 3 (15)
Stent breakage 0 1 (5)
Bleeding 0 2 (10)
Aspiration 1 (3.1) 0
Pain, dysphagia 0 1 (5)
Regurgitation, oesophagitis 0 2 (10)
*Due to tumour growth after laser therapy, and tumour overgrowth (3), oesophageal stricture
(1), and food bolus (1) after stent placement.
palliation than have plastic prostheses12, 16, 17. Based on all these reports,
no firm conclusion can be reached regarding the best palliation of
tumours near the GE junction. On the other hand, one has to remember
that a long, tortuous stricture, especially with extrinsic compression, is
difficult to palliate with laser therapy12.
Because of the short life-expectancy and high one-off costs,
placement of SEMS did not reduce the overall cost of palliation despite
the reduced need for reinterventions. The most important factor affecting
the quality of life in these patients is severity of dysphagia18. It is
debatable whether the increased number of interventions is even a
burden to the patient, because regular contact with specialists may
provide counselling and support of great importance to these dying
patients. Overall, that the time spent in hospital did not differ between
the study groups means that for none of these patients with their limited
lifespan, was the opportunity to spend time with family and friends
reduced.
That no survival difference existed between treatment groups agrees
with previous findings8, 16. However, procedure-related complications
and mortality cannot be disregarded. In this study, morbidity and early
mortality were significantly more common with SEMS than with laser
therapy. In the stent group higher morbidity and early mortality increased
the overall costs and the cost per day of palliation. The early complication
rate of 30% after placement of SEMS equals the figure recently reported
in a critical review of SEMS15. Complication rates are high, especially in
treatment of tumours near the GE junction6. The advantage of laser
therapy is the low procedure-related morbidity and mortality rates,
although perforation occurs in a few cases19. In addition, this study
showed no difference in the rate of late complications between laser
therapy and placement of SEMS.
No sign of significant difference between the study groups could be
detected in total costs. This finding is likely to hold even with a more
detailed and complex analysis, although this relatively small retrospective
study has its potential flaws. Therefore, the choice between these
endoscopic treatment modalities should be based on medical – not
financial – arguments.
In conclusion, it seems that laser therapy palliates dysphagia of
patients with adenocarcinoma at the distal oesophagus or at the GE
junction effectively without increased costs or hospital stays and with
lower morbidity and early mortality rates than for self-expanding
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seems not even to affect life expectancy (Shaheen et al. 2000, Eckardt et
al. 2001).
The substantial length of Barrett’s (>8-10 cm) mucosa seems to be
a risk factor in the development of cancer (Iftikhar et al. 1992, Dees et al.
1996, Weston et al. 1999, Rudolph et al. 2000), though the risk with
short-segment Barrett’s mucosa (<3 cm) has not been substantially
lower than for longer segments (3-10 cm) (Rudolph et al. 2000). The
presence of dysplasia – especially high-grade dysplasia (HGD) – hiatal
hernia size, and the presence of Barrett’s ulcer have been other features
recognized as predictive of development of adenocarcinoma (Dees et al.
1996, Weston et al. 1999). The dysplasia risk, and therefore probably
the overall malignant potential of intestinal metaplasia distal to the
squamocolumnar junction is significantly less (Sharma et al. 2000).
In HGD, up to 61% of patients have developed esophageal
adenocarcinoma during a median time of 8 months (Montgomery et
al. 2001), and 39% of 262 patients with HGD in all the series found in
the literature have already had cancer at the time of esophageal
resection (Edwards et al. 1996, Heitmiller et al. 1996, Ferguson and
Naunheim 1997, Cameron and Carpenter 1997, Catatrambone et al.
1999, Ngueyn et al. 2000, Zaninotto et al. 2000, Headrick et al. 2002).
Smoking and alcohol are well-known risk factors for esophageal
squamous cell carcinoma. For esophageal and gastric cardia
adenocarcinoma, although equivocal evidence has been reported, four
recent studies revealed a modest risk from smoking (Kabat et al. 1993,
Vaughan et al. 1995, Zhang et al. 1996, Gammon et al. 1997). This risk
seems to be more than double that of the normal population, with a
dose-response pattern (Vaughan et al. 1995, Zhang et al. 1996). Recent
epidemiological studies demonstrate only a weak association or none
between alcohol consumption and these adenocarcinomas (Vaughan et
al. 1995, Zhang et al. 1996, Gammon et al. 1997).
Other reports have indicated a protective role for dietary fiber
intake in risk for these adenocarcinomas (Brown et al. 1995, Zhang et al.
1997). Only two studies have evaluated the association of dietary fiber
and adenocarcinoma of the esophagus or gastric cardia separately
(Mayne et al. 2001, Terry et al. 2001). Both of these studies showed an
inverse association between fiber intake and risk for adenocarcinoma of
the gastric cardia, but only Mayne et al (2001) established an inverse
association between fiber intake and esophageal adenocarcinoma, as
well.
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Obesity seems to be a risk factor for esophageal adenocarcinoma
and for cancer of the gastric cardia (Brown et al. 1995, Vaughan et al.
1995, Chow et al. 1998a, Lagergren et al. 1999b). One possible
explanation is that increased abdominal girth promotes gastroesophageal
reflux, which, in turn, is a known risk factor for esophageal adeno-
carcinoma (Lagergren et al. 1999a). Higher prevalence of gastro-
esophageal reflux may also be the link between increased risk for
esophageal adenocarcinoma and the use of drugs with the side-effect of
relaxing the lower esophageal sphincter (LES) (Vaughan et al. 1998,
Lagergren et al. 2000).
An inverse relation seems to exist between the incidence of
esophageal and gastric cardial adenocarcinoma and the prevalence of
Helicobacter pylori (Chow et al. 1998b, Hansen et al. 1999). The possible
protective effect against esophageal adenocarcinoma of H. pylori
infection with the cagA+ strain may be due to decreased intragastric
acid production as a result of pangastritis and gastric atrophy (Richter
et al. 1998).
5.5 Barrett’s esophagus and adenocarcinoma
Long-lasting gastroesophageal reflux disease, oxidative stress, and
angiogenesis in the esophageal mucosa each seems to play a role in the
pathogenesis of Barrett’s esophagus, and esophageal adenocarcinoma.
GASTROESOPHAGEAL REFLUX
The definition of Barrett’s esophagus has now evolved to these findings:
biopsy-confirmed intestinal metaplasia with goblet cells in the tubular
esophagus any distance proximal to the gastric folds (Sharma 2001).
This specialized intestinal metaplasia is a complication of gastro-
esophageal reflux disease. Among 248 GERD patients in one Finnish
series, prevalence of Barrett’s esophagus was 4% (Voutilainen et al.
2000).
Long-lasting gastroesophageal reflux causes chronic esophageal
mucosal damage with metaplastic epithelium replacing damaged
squamous epithelium. The main contributors to this damage are acid
and pepsin (Salo and Kivilaakso 1982, Zaninotto et al. 1992). Duodenal
contents play a role in this process as well (Salo and Kivilaakso 1983,
Vaezi and Richter 1996, Öberg et al. 2000, Martinez de Haro et al.
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2001). An incompetent LES, the presence and size of any hiatal hernia,
ineffective esophageal clearance, and delayed gastric emptying increase
exposure of these reflux-contents in patients with Barrett’s esophagus
(Stein et al. 1993, Singh et al. 1994, Öberg et al. 1999, Cameron
1999). The presence of cytokeratins characteristic of normal esophageal
squamous epithelium in Barrett’s mucosa supports the current theory
that the stem cells of the squamous mucosa undergo altered
differentiation and give rise to intestinal metaplasia (Salo et al. 1996).
It is assumed that this metaplastic epithelium is better able to resist
the adverse effects of the duodenal and gastric contents.
Intestinal metaplasia in the distal esophagus, regardless of its
length, has shown increased proliferative activity and has progressed
to dysplasia and adenocarcinoma (Gulizia et al. 1999, Sharma et al.
2000). In this metaplasia-dysplasia-adenocarcinoma sequence,
accumulation of changes occurs in genes controlling cell proliferation,
apoptosis, cell cycle, cell adhesion, gene expression, and in DNA and
in chromosomes (Wu et al. 1998, Wijnhoven et al. 2001, Jenkins et al.
2002). The balance between cell proliferation and cell loss is, therefore,
disturbed (Wijnhoven et al. 2001).
The pathogenesis of adenocarcinoma at the gastric cardia is less
clear. Whether the intestinal metaplasia at the gastric cardia is a
consequence of gastroesophageal reflux or a manifestation of gastritis
caused by Helicobacter pylori is disputed (Spechler 1999). In gastro-
esophageal reflux disease, mucosal injury at the gastric cardia is highly
localized to the region adjacent to the squamocolumnar junction
(Lembo et al. 1999). It seems that incomplete intestinal metaplasia
(specialized columnar epithelium) may result from reflux disease, and
the complete type of intestinal metaplasia may be associated with
atrophic gastritis (Voutilainen et al. 1999). In a recent study, of 16
patients, 11 (69%) had incomplete intestinal metaplasia in the mucosa
adjacent to adenocarcinoma at the gastric cardia (Ruol et al. 2000).
Adjacent to adenocarcinoma, low-grade and high-grade dysplasia
have been discovered as well (Van Dekken et al. 2001).
OXIDATIVE STRESS
Although the esophagitis-metaplasia-dysplasia-cancer sequence is clear,
the molecular mechanisms leading to genetic changes, and also to
adenocarcinoma are not well defined. In the development of
adenocarcinoma, oxidative stress has been suggested as a driving force
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(Cheng and Yang 2001). Oxidative stress plays a role in the
pathomechanism by which tissue injury occurs in esophagitis and in
Barrett’s epithelium (Olyaee et al. 1995, Wetscher et al. 1995, Oh et al.
2001). In a recent epidemiological study, an inverse association appeared
between antioxidants and the risk for adenocarcinoma of the esophagus
(Terry et al. 2000). In addition to increased oxidative stress, low
antioxidant capacity, seen as low content of glutathione and as reduction
in glutathione S-transferase activity, may be a factor of relevance in this
process (Peters et al. 1993, Van Lieshout et al. 1999). No direct link
between reactive oxygen species and malignant transformation of the
esophageal mucosa caused by GERD has, however, yet been established
(Cheng and Yang 2001, Farhadi et al. 2002).
Free radicals such as the superoxide and hydroxyl radical are
extremely reactive chemical species which can cause oxidative injury to
cells by damaging proteins, cell membranes, or DNA. Deficiency in
antioxidant defence further amplifies oxidative stress and tissue injury
(Dreher and Junod 1996). The importance of oxidative stress has
attracted notice in relation to formation of DNA adducts (Kasai and
Nishimura 1984, Dreher and Junod 1996); high levels of DNA adducts
have been discovered in Barrett’s epithelium (Salminen, in press). By
adding a small chemical group to a DNA-base, these DNA adducts
can interfere with DNA replication and therefore initiate mutagenic
and carcinogenic processes by producing mispaired DNA sequences
(Denissenko et al. 1996, Ross and Nesnow 1999).
ANGIOGENESIS AND LYMPHANGIOGENESIS
For the continuous growth of tumors beyond the diffusion limit of
oxygen, they must recruit new blood vessels (Carmeliet and Jain 2000).
This formation of new blood vessels from pre-existing ones – angiogenesis
– occurs, therefore, in tumor progression. Recently, high vascularization
in esophageal adenocarcinoma and the adjacent intestinal metaplasia
was disclosed (Couvelard et al. 2000, Millikan et al. 2000). In brief, the
process of angiogenesis consists of three steps: 1) Local degradation of
capillary basement membrane, 2) migration and proliferation of
endothelial cells, and 3) organization of endothelial cells into three-
dimensional capillary tubes (Fidler et al. 2000). The angioarchitecture
within Barrett’s epithelium is uncharacterized. In tumor tissue, these
new vessels are structurally and functionally abnormal (Carmeliet and
Jain 2000).
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The onset and process of angiogenesis requires a change in the local
equilibrium between pro- and antiangiogenic factors (Liotta et al. 1991,
Hanahan and Folkman 1996). This equilibrium can be unsettled by
various signals including hypoxia, metabolic and mechanical stress,
inflammatory response, and genetic mutations (Shweiki et al. 1992, Rak
et al. 1995, Carmeliet and Jain 2000). In the metaplasia-dysplasia-
adenocarcinoma sequence in the esophagus, several potential factors
stimulating angiogenesis exist (Table 2). Vascular endothelial growth
factor (VEGF), expressed both in Barrett’s esophagus and in related
adenocarcinoma, is considered the most critical driver of angiogenesis
(Yancopoulos et al. 2000).
TABLE 2 Known angiogenesis activators found in the metaplasia-dysplasia-
adenocarcinoma sequence in Barrett’s esophagus
Angiogenesis activator Author
Vascular endothelial growth factor (VEGF) Couvelard et al. 2000
Transforming growth factor-beta (TGF-b) Triadafilopoulo and Kumble 1996
Fibroblast growth factor (FGF) Soslow et al. 1997
Matrix metalloproteinase (MMP) Salmela et al. 2001
Cyclooxygenase (COX-2) Morris et al. 2001
Nitric oxide synthase (NOS) Soteras et al. 2000
Angiogenesis provides a vascular route for the hematogenous spread
of cancer cells. In several cancers, angiogenesis has been revealed as a
significant negative prognostic factor (Toi et al. 1993, Weidner 1995,
Yuan et al. 2001), but in esophageal adenocarcinoma, results have
been equivocal (Torres et al. 1999, Millikan et al. 2000, Couvelard et
al. 2000). On the other hand, esophageal adenocarcinoma spreads
early into the lymphatic system. This implicates lymphangiogenesis,
the growth of new lymphatic vessels, in early lymphatic spreading of
this disease. A strong promoter of lymphangiogenesis in tumor tissue
is vascular endothelial growth factor C (VEGF-C) (Karpanen et al.
2001), which is expressed in several human cancers including esophageal
squamous cell cancer (Akagi et al. 2000, Kitadai et al. 2001, Yonemura
2001). The expression of VEGF-C and tumor-related lymphangiogenesis
has been correlated with increased dissemination of tumor cells into
lymph nodes (Akagi et al. 2001, Skobe et al. 2001).
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5.6 Staging
Pre-therapeutic staging of adenocarcinoma near the EG junction is a
prerequisite for the proper selection of treatment. The main goal is to
evaluate whether a complete tumor resection can be achieved.
Staging is usually conducted in accordance with International
Union Against Cancer (UICC) TNM staging (UICC 1997) (Figure 3).
TNM stage is determined by evaluation of tumor infiltration into the
organ wall (T stage), of lymph node status (N stage), and of the
presence or absence of distant metastases (M stage). The presence of
distant metastases (M1 disease) is further divided into two subclasses:
M1a (distant, nonregional lymph node metastases) and M1b (other
distant metastases).
In the case of distant metastases, no curative treatment is possible.
To assess for distant metastases (M1b disease), computed tomography
(CT) is widely used. The problem even with modern CT technology is,
however, its inability to detect small (< 1 cm in diameter) metastases.
Overall, CT has a relatively low sensitivity, less than 50%, and specificity
between 74% and 83% in detecting M1b disease (Luketich et al. 1999,
Flamen et al. 2000). Recent studies indicate that positron emission
tomography (PET) is superior to CT (accuracy 84% vs. 63%, p<0.01), or
to combined use of CT and endoscopic ultrasound (EUS) (accuracy 82%
vs. 64%, p=0.004) (Luketich et al. 1999, Flamen et al. 2000). PET
frequently fails, however, to detect small and distant, especially liver and
peritoneal, metastases (Luketich et al. 1999, Flamen et al. 2000). To
avoid unnecessary laparotomy, a diagnostic laparoscopy can, therefore,
be used in patients with locally advanced tumors (Stein et al. 1997).
Local tumor infiltration into surrounding structures and wide-
spread lymph node involvement significantly reduces the likelihood of
achieving a complete tumor resection. Endoscopic ultrasound predicts
T stage in esophageal cancer most reliably with a diagnostic accuracy
of 84% (Rösch 1995). In a recent study of adenocarcinoma of the
esophagus and EG junction, T stage was correct in only 66% (Salminen
et al. 1999). In these patients, EUS predicted resectability with 94%
accuracy (Salminen et al. 1999).
Though in experienced hands using a combination of EUS and
ultrasound, widespread lymphatic metastases can be predicted with
high accuracy (96%), N staging is currently considered of little importance,
because it cannot be assessed with sufficient accuracy (Stein 2001,
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FIGURE 3 TNM staging of esophageal carcinoma
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Natsugoe et al. 2001). In a recent meta-analysis, the accuracy of EUS in
detection of N stage in esophageal cancer was 77% (Rösch 1995). In
adenocarcinoma in the distal esophagus and EG junction, EUS predicted
N stage correctly in 72% of patients (Salminen et al. 1999). The inability
to pass the probe through obstructing tumors is a limitation which can
have a major effect on reliability of EUS in determination of the status of
celiac nodes (M1a disease) (Salminen et al. 1999). The ability of EUS to
assess the status of celiac nodes, regardless of these limitations, is
considered to be high (Catalano et al. 1999). Patients with EUS M1a
disease have significantly worse 5-year survival than with non-detected
M1a disease (30% vs. 13%) (Eloubeidi et al. 2001).
It is evident that lack of accuracy in these pre-therapeutic staging
methods makes it difficult precisely to define completely resectable
disease. The transmural nature of these tumors has, however, been
predicted with high accuracy with EUS (Salminen et al. 1999). The
prevalence of positive lymph nodes has been 83% in T3 and 96 to 100%
in T4 tumors compared to 1 to 3% in mucosal, 19 to 21% in submucosal,
and 46 to 77% in T2 tumors (Rice et al. 1998, Stein et al. 2000a). The
chance for complete resection has depended on T-stage as well (69%
in T3, 59% in T4) (Stein et al. 2001). Patients with T3/4 tumors
detected by EUS may therefore be candidates for multimodality therapy
(Stein et al. 2001). When the disease is limited to the esophageal wall
(T1/2), primary resection is the treatment of choice.
5.7 Treatment
In the population-based study by Allum (1986) in the 1970’s, 36% of
patients with adenocarcinoma at the gastric cardia underwent radical
resection, 19.9% received no treatment, and the others were treated
palliatively, most either with resection or with esophageal intubation.
Even in a recent analysis, only one-third of patients with adenocarcinoma
at the esophagus could be offered surgery (Daly et al. 2000); in that
large hospital-based series, up to 44% of patients received primarily only
radiation, chemotherapy, or both, and 15.4% received no specific
treatment. Though endoscopic treatment modalities such as stents or
laser therapy play an important role in palliation of these patients, the
overall role of these endoscopic interventions at the population level is
not well characterized.
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SURGICAL TREATMENT
In adenocarcinoma of the distal esophagus or the EG junction, surgery
is generally considered to offer the best chance for curing the patient
and restoring satisfactory swallowing. Beyond this basic principle,
controversies exist as to the proper choice of surgical approach and
extent of resection, and as to the role of lymphadenectomy. To answer
such questions, no good prospective randomized studies have been
conducted. Choice of surgical approach depends on the location of
the tumor, stage of the disease, patient characteristics, and, especially,
the surgeon’s attitude towards lymphadenectomy and resection
margins. A combined right thoracotomy and laparotomy is the preferred
approach (Siewert and Bumm 1997). This approach provides the best
visibility to perform mediastinal lymphadenectomy and to resect the
esophagus with a margin sufficiently wide.
In a recent study by Dexter (2001), the finding of a tumor within
one millimeter of the proximal esophageal resection margin with
potentially curable disease was a significant predictor both of local
recurrence and of survival. Previously, the same local recurrence rate
was detectable in patients with free proximal resection margins of less
than 3 cm compared to those with positive margins (Molina et al.
1982). Though a safety margin of 2 to 3 cm is considered to be
sufficient in intestinal-type tumor growth (Siewert et al. 2000), only
with wide resections (10-12 cm margins) have there been no positive
margins (Papachristou et al. 1980, Peracchia et al. 1991). The extent
of the distal resection needed has been less well studied. Especially
adenocarcinomas at the gastric cardia frequently (28%) have positive
distal resection margins (Casson et al. 2000). These positive distal
margins also have a negative effect on survival, leading Casson et al
(2000) to recommend a minimum resection of macroscopically normal
stomach to 5 cm below the tumor.
The role of radical lymphadenectomy in surgery for esophageal
cancer is a debated topic. In patients with early adenocarcinoma near
the EG junction, limited resection with locoregional lymphadenectomy
and possibly with vagal preservation seems to be safe and preserves a
good quality of life (Nigro et al. 1999b, Stein et al. 2000b). The long-
term results of this limited approach are, however, lacking. In more
advanced disease, radical surgery with lymphadenectomy seems to end
in better control of local recurrence and improved pathologic staging,
and the likelihood of obtaining complete resection (Altorki et al. 1997,
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Lerut et al. 1999, Van de Ven et al. 1999, Hagen et al. 2001). The most
important concern, of course, is whether more radical lymph node
dissection really contributes to improvement in survival. Those patients
who potentially would benefit from more extentive resections have only
a few metastatic lymph nodes (Nigro et al. 1999a). In a recent analysis,
25% of patients with transmural esophageal adenocarcinoma and lymph
node metastases were alive at 5 years (Hagen et al. 2001). In another
study, patients with limited lymph node metastases (<5) had a 5-year
survival rate of 37% (Collard 2001). In a large series by Orringer (1999),
overall 5-year survival after transhiatal technique was 24%.
The systematic nature of the disease and the ineffective role of
radical lymph node dissection in gastric cancer raise some questions as
to the role of lymphadenectomy (Bonenkamp et al. 1999, O’Sullivan et
al. 1999). More radical operations are therefore justified only if they can
be performed without significantly increased mortality and morbidity. A
prospective randomized study of 32 patients comparing a radical en-
block technique with 2-field lymphadenectomy and standard resection
showed prolonged duration of surgery and increased blood loss in the
lymphadenectomy group but no difference in postoperative morbidity
or mortality (Jacobi et al. 1997). Nor did two other randomized studies
comparing transhiatal and transthoracic resections show any differences
in postoperative complications (Goldminc et al. 1993, Chu et al. 1997).
In a recent meta-analysis, transthoracic resections resulted in a higher
risk for pulmonary complications, chylous leakages, and wound infections
(Hulscher et al. 2001). In the same meta-analysis, on the other hand, the
transhiatal technique more frequently resulted in anastomotic leakage
and vocal cord paralysis; in addition, only transhiatal resections had
severe bleedings or tracheal tears peroperatively. Though the perioperative
mortality rate in that meta-analysis was significantly higher after
transthoracic resection, the randomized trials had the opposite tendency,
with lower mortality in the transthoracic group. The excellent results of
Orringer in a large transhiatal series weigh heavily in this meta-analysis
(Orringer et al. 1999, Hulscher et al. 2001). In experienced centers, low
mortality rates can be achieved by the more radical en-block technique,
as well (Altorki et al. 1997, Hagen et al. 2001, Collard 2001).
Previously, esophagectomy had the highest surgical mortality (29%)
of any routinely performed surgical procedure (Earlam and Cunha-
Melo 1980). Similarly, radical resection of adenocarcinoma at the
gastric cardia carried a 30-day mortality of 19% (Allum et al. 1986). In
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two recent meta-analyses, mortality rates after esophageal resection
were 7.5% and 11.0% (Jamieson et al. 1998, Hulscher et al. 2001). The
complication rate in surgery for adenocarcinoma near the EG junction,
even in experienced units, has ranged from 28% to 71% (Ellis et al.
1997, Hagen et al. 2001). Increasing evidence indicates that surgical
volume and experience both have major impact on surgical mortality
and on early outcome after major cancer surgery, especially after
esophagectomy (Begg et al. 1998, Sutton et al. 1998, Swisher 2000,
Whooley et al. 2001).
In the 1960’s and 70’s, the 5-year survival rate after esophagectomy,
according to Earlam’s large review, was 12% (Earlam and Cunha-Melo
1980). Similarly, a population-based analysis of radical resection of
adenocarcinoma at the gastric cardia revealed a 5-year survival rate of
only 9.8% (Allum et al. 1986). In the late 1980’s in Denmark, 5-year
survival after surgery for esophageal adenocarcinomas was 17% (Bytzer
et al. 1999), but in two recent Western meta-analyses, 5-year survival
after esophagectomy was 20.6% and 21.4% (Jamieson et al. 1998,
Hulscher et al. 2001). In recent selected surgical series, 5-year survival
in adenocarcinoma of the distal esophagus and EG junction has been
over 30% (Siewert et al. 2000, Collard 2001). Outcome of surgical
treatment in the recent literature is shown in Table 3.
TABLE 3 Outcome of surgical treatment in patients with adenocarcinoma of the
esophagus or esophagogastric junction in the recent literature
Author (year) No. of patients Morbidity 30-day 5-year
(timing of treatment) (%) mortality (%) survival (%)
Harvey (1990) 58 (1954-88) NA 9 8
Wilson (1990) 25 (1982-87) 40 0 0
Streitz (1991) 61 (1973-89) 21.3 3.3 23.7
Menke-Pluymers (1992) 85 (1978-88) 34 6 24
Moon (1992) 88 (1974-90) 43 10.3 13
Law (1992) 92 (1982-89) NA 6.5 15
Gelfand (1992) 121 (1979-90) NA 2.5† 21†
Lerut (1994) 63 (1975-91) 9.5 0 58.2
Stark (1996) 48 (1988-94) NA 2.1 21
Ellis (1997) 303 (1979-94) 27.9† 2.5† 24.7†
Alexiou (1998) 339 (1987-97) 28.1† 5.4† 23.8†
Graham (1998) 153 (1985-97) NA 4* 16
Hoff (1998) 70 (1988-96) NA 0 43
Orringer (1999) 555 (1976-98) NA 4.5* 24
Siewert (2000) 1002 (1982-99) NA 3.8 32.3
Collard (2001) 183 (1984-2000) NA 4.3 35.3
Mattioli (2001) 116 (1972-98) NA 6.9 26.2
Altorki (2001) 81 (1988-98) 49 3.6† 40†
Hagen (2001) 100 (1982-2000) 71 6 52
NA, not available; *Hospital mortality
†Morbidity, mortality, and 5-year survival refer to overall number of patients in studies by Ellis
(n=454), Alexiou (n=523), Gelfand (n=160), and Altorki (n=111).
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ENDOSCOPIC TREATMENT
Even at presentation, over 60% of patients with adenocarcinoma near
the EG junction have incurable disease, either because of their advanced
stage or poor general physical condition (Allum et al. 1986, Daly et al.
2000). For the majority, the main aims of treatment are palliation of
dysphagia, prevention of aspiration, and improvement in quality of
life. The role of palliative surgery is very limited, because of the related
morbidity, mortality, and short life-expectancy (Sugimachi et al. 1982,
Mannell et al. 1988).
Continuous debate in the literature confirms the fact that none of
the palliative methods to treat esophageal cancer is entirely optimal.
Obstructive carcinomas of the EG junction are especially difficult to
palliate (Warren 2000, Kubba and Krasner 2000). Most clinicians
elect primarily one of the endoscopic treatment modalities, which can
be classified as esophageal stents – either rigid plastic or self-expanding
metallic stents (SEMS) – and such local tumor ablation techniques as
laser therapy.
Laser therapy has provided better palliation than have plastic
prostheses (Alderson and Wright 1990, Carter et al. 1992). Similarly,
self-expanding metallic stents have been proven superior to esophageal
intubation with plastic prostheses (Knyrim et al. 1993, DePalma et al.
1996, Siersema et al. 1998). Due to a lower complication rate, shorter
hospital stay, and simplicity of placement, expandable stents have
gained wider acceptance than have the traditional plastic stents (Knyrim
et al. 1993, DePalma et al. 1996, Siersema et al. 1998). Regardless of
these improvements, a critical review of reports on SEMS observed a
high rate of early and late complications such as stent migration,
incomplete expansion, and tumor ingrowth (Ell and May 1997).
Covered stents are prone to migration at the EG junction; the particular
problem of uncovered stents is tumor ingrowth (Adam et al. 1997,
Kozarek et al. 1997, Vakil et al. 2001).
Because stenting of tumors near the EG junction predisposes to
reflux, migration, and ingrowth, the preferred palliative method in this
area is often laser therapy (Wengrower et al. 1998, Gevers et al. 1998).
No prospective randomized studies compare laser therapy and SEMS
in the treatment of malignant dysphagia purely due to carcinomas of
the EG junction. Regarding a more proximal location, one prospective
randomized trial showed SEMS to offer better palliation of dysphagia
than did laser therapy, but over 40% of the tumors involved were
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located in the middle or upper esophagus (Adam et al. 1997).
Based on all these reports, no firm conclusion can be reached
regarding the best palliation of tumors near the EG junction. No survival
difference has appeared between different endoscopic treatment groups
(Carter et al. 1992, DePalma et al. 1996). One has to remember,
however, that a long, tortuous stricture, especially with extrinsic
compression, is difficult to palliate with laser therapy (Alderson and
Wright 1990).
MULTIMODALITY THERAPY
In an attempt to improve the results of surgical therapy for esophageal
cancer, preoperative chemotherapy, radiation, or both have been
added to enhance local control, increase resection rate, provide better
systemic control of the disease, and improve survival. A meta-analysis
including both main histological subtypes of esophageal cancer
(squamous cell and adenocarcinoma), and the only existing prospective
randomized trial including mainly patients with adenocarcinoma (73%)
demonstrated no improvement in resectability or survival after
preoperative radiotherapy (Arnott et al. 1992, 1998).
The results of randomized studies of preoperative chemotherapy
including a large number of esophageal adenocarcinoma patients are
conflicting. In the multicenter North American trial, median (15 vs. 16
months) and 2-year (35 vs. 37%) survivals were similar in patients
receiving chemotherapy and surgery versus surgery alone (Kelsen et al.
1998). Conversely, the results of a recently completed randomized
trial showed, after neoadjuvant chemotherapy, a higher microscopically
complete resection rate (60 vs. 54%, p<0.0001), an improved median
(16.8 vs. 13.3 months; difference 107 days, 95% CI 30-196), and 2-
year survival (43 vs. 34%; difference 9%, 95% CI 3-14) (Medical Research
Council 2002).
In a recent meta-analysis, those studies in which the majority of
patients had esophageal adenocarcinoma showed preoperative
chemoradiotherapy to have a 24% pathologically complete response
rate which varied between 17% and 41% (Naunheim et al. 1995,
Forastiere et al. 1999, Geh et al. 2001). Median survival was between
16 and 31 months and 5-year survival up to 36% (Geh et al. 2001). A
prospective randomized study by Walsh (1996) showed a survival
benefit in favor of chemoradiotherapy compared to surgery alone
(median survival 16 vs. 11 months, p=0.01; 3-year 32 vs. 6%, p=0.01)
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with 22% complete pathological response. The other randomized trial,
as well, showed some trend toward benefit from chemoradiotherapy
(median 17.6 vs 16.9 months; 3-year 30 vs. 16%, p=0.15), but the
study had power to detect only relatively large differences (Urba et al.
2001). It seems evident that those patients with a histologic complete
response do benefit from preoperative chemoradiation (3-year survival
64 vs. 19%, p=0.01) (Urba et al. 2001). On the other hand, this kind of
neoadjuvant treatment has potentially deleterious effects on patients’
working capacity and increases risk for complications (Liedman et al.
2001).
5.8 Prognosis in adenocarcinoma of the esophagus and
esophagogastric junction
Before the 1980’s, the 5-year survival of esophageal adenocarcinoma
was 2.7% and 3.7% at the EG junction (Allum et al. 1986, Matthews
and Walker 1990). In the 1980’s, survival at one year was less than
30% and remains less than 10% at 5 years (Farrow and Vaughan 1996,
Bytzer et al. 1999, Dolan et al. 1999).
Patients ineligible for treatment generally survive for about 2
months (Allum et al. 1986, Harvey et al. 1990). In advanced disease,
possibly with organ metastases or peritoneal carcinosis, chemotherapy
or radiation as a single treatment modality is ineffective (Whittington
et al. 1990), and median survival after palliative radiation has been
less than 6 months (Cederqvist et al. 1980, Harvey et al. 1990). In
patients with a good response rate to chemotherapy, median survival
can be up to 9 months (Waters et al. 1999). Combined radiation and
chemotherapy in palliative treatment have had similar results (Coia et
al. 1988). Only selected patients with adenocarcinoma near the EG
junction have lived past 5 years when treated with chemoradiotherapy
with curative intent (Coia et al. 1988, Cooper et al. 1999). Patients
with malignant dysphagia treated with endoscopic treatment modalities
have generally had a median survival of between 3 and 6 months
(Loizou et al. 1991, Carter et al. 1992, Knyrim et al. 1993).
In patients with locoregional disease, the most important
prognostic factor is complete macroscopic and microscopic tumor
resection (R0 resection) (Hölscher et al. 1995, Siewert et al. 2000,
Collard 2001). In recent studies, 5-year survival after R0 resection has
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been 39% to 48%, compared to only 0 to 14% after incomplete
resection (Hölscher et al. 1995, Siewert et al. 2000, Collard 2001).
After a complete resection, the major independent prognostic
factors are depth to which the tumor has invaded the esophageal wall,
lymph node status, number of positive lymph nodes, and ratio of
involved to uninvolved nodes (lymph node ratio) (Lerut et al. 1994,
Hölscher et al. 1995, Collard 2001, Hagen et al. 2001). Tumor depth
predicts both prevalence and the number of involved nodes (Rice et al.
1998, Hagen et al. 2001). In a series by Collard (2001), node-negative
patients with tumors limited to the esophageal wall had an 84% 5-year
survival rate compared to 44% in patients with transmural node-
negative tumors. When the number of involved nodes increases to
more than 4 to 6, or the lymph node ratio is above 0.3, probability of
long-time survival falls to less than 10% (Hölscher et al. 1995, Bonavina
et al. 1999, Collard 2001). The extent of lymph node involvement is
underestimated in routine histological examination, and it seems that
lymph node micrometastases also have a negative effect on long-term
survival (Bonavina et al. 1999).
DNA content analysis can be a valuable adjunct to the current
prognostic evaluation (Wu et al. 1998, Böttger et al. 1999). Böttger et al
(1999) suggested that patients with aneuploid DNA do not benefit from
surgery alone. Other factors that may have an adverse effect on prognosis
are low experience of the center and the surgeon (Sutton et al. 1998),
increased number of blood transfusions required perioperatively (Karl
et al. 2000, Langley et al. 2002), surgical morbidity (Ando et al. 2000),
preoperative weight loss (Fein et al. 1985), absence of a peritumoral
lymphoid infiltrate (Torres et al. 1999), and expression of certain
immunohistochemical tumor markers such as high-level expression of
p53, low level of transforming growth factor-α, low level of P-glycoprotein,
and expression of epidermal growth factor receptor and of the c-erB-2
oncogene (Flejou et al. 1994, Yacoub et al. 1997, Schneider et al. 2000,
Aloia et al. 2001). A marker profile (a combination of negative markers)
could, ideally, guide the selection of patients for neoadjuvant or adjuvant
therapies (Aloia et al. 2001).
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6 AIMS OF THE PRESENT STUDY
I To evaluate changes in the incidence of adenocarcinoma of the
esophagus and gastric cardia in Finland during the 20-year period
1976 to 1995.
II To evaluate the role of oxidative stress and radical scavenger capacity
in the pathogenesis and malignant transformation of Barrett’s
esophagus by measuring the parameters of oxidative metabolism
and DNA adducts in GERD without and with endoscopic esophagitis,
in Barrett’s metaplasia without and with dysplasia, in esophageal/
esophagogastric junction adenocarcinoma, and in a control group.
III To evaluate the extent and role of angiogenesis and lymphangio-
genesis in Barrett’s mucosa and adenocarcinoma, and the
morphology of this new vascular bed.
IV To evaluate the outcome of patients with adenocarcinoma at the
distal esophagus and esophagogastric junction undergoing current
treatment and to compare the results of different types of therapeutic
procedures.
V To compare relative lifetime costs and clinical results of the Nd:YAG
laser to those of SEMS as alternative forms of primary palliation of
dysphagia for adenocarcinoma of the distal esophagus and
esophagogastric junction.
AIMS OF THE PRESENT STUDY
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7 PATIENTS AND METHODS
7.1 Patients
The primary data for Studies I and IV came from the Finnish Cancer
Registry (FCR). FCR, population-based and covering all parts of Finland,
receives notifications of tumors independently from hospitals,
physicians, pathological and hematological laboratories, and forensic
autopsies. In addition, all death certificates in which cancer is mentioned
are transferred each year from the files of Statistics Finland to the
Cancer Registry. Multiple sources of notification at different phases of
the disease improve registration coverage. On average, there are five
notifications per cancer case. The quality of the Finnish Cancer Registry
has been evaluated through linkage of the files of FCR with hospital
discharge registry records. For solid tumors, coverage has been shown
to be more than 99% (Teppo et al. 1994).
STUDY I
All primary malignant neoplasms of the esophagus (n=4302)
(International Classification of Diseases for Oncology [ICDO] site
code 150) and adenocarcinoma of the gastric cardia (n=1956) (ICDO
site code 151.0) diagnosed between 1976 and 1995 in Finland,
excluding rare types of esophageal cancer, were included in this analysis
(World Health Organization 1976). The total number of esophageal
cancers so excluded was 112 (2.6%). Esophageal cancers were divided
according to ICDO morphology criteria into squamous-cell carcinoma,
adenocarcinoma, neoplasms not otherwise specified, and those without
histology (World Health Organization 1976).
STUDY II
This study included 52 patients. Mean age was 54.6 years (range 25-
77): Thirteen had symptomatic GERD with pathological 24-h pH
measurement, of whom eight had normal esophageal mucosa, and
five mild grade-1 or -2 endoscopic esophagitis according to the Savary-
Miller classification system (Savary and Miller 1978). In GERD, the
histologic findings were classified according to the modified
morphologic criteria of Richardson et al (1983). Endoscopic normal
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esophageal mucosa revealed no change or indefinite changes in seven
patients and mild changes in one; in grade-1 or –2 esophagitis, four
patients had no change or indefinite changes, and one had mild
changes. Thirteen had Barrett’s esophagus with histologically proven
intestinal metaplasia in the distal esophagus, of whom eight had
intestinal metaplasia without dysplasia, and five low-grade dysplasia.
Dysplasia was classified according to previously established criteria
(Riddell et al. 1983). All patients with Barrett’s esophagus had reflux
symptoms and pathological 24-h pH measurements. Of the 19 patients
with adenocarcinoma of the distal esophagus/esophagogastric
junction, six had adenocarcinoma in a histologically confirmed Barrett’s
esophagus. Controls were seven patients without symptoms or
endoscopic evidence of esophageal pathology.
STUDY III
Barrett’s mucosa samples were collected from 15 patients who
underwent surgical resection of Barrett’s dysplasia (4 patients) or
adenocarcinoma (11 patients) between March 1998 and November
2000. Previously, the presence of specialized intestinal metaplasia in
the esophagus had been confirmed.
STUDY IV
A search in the Finnish Cancer Registry identified 482 primary adeno-
carcinomas of the esophagus (ICDO site code 150) and adenocarcinomas
of the gastric cardia (ICDO site code 151.0) (World Health Organization
1976), or registrations mentioning one of these from 1990 to 1998 in
Uusimaa and Pirkanmaa, two Finnish health-care districts with a total
population of 1 750 000. Each diagnosis had been made endoscopially
or at autopsy and confirmed by histologic examination of the biopsy
specimen. The histology and location of each tumor were verified; 73
gastric-cancer patients were excluded, plus one each with esophageal
squamous cancer, esophageal adenosquamous cancer, adenocarcinoma
in the cervical esophagus, pancreatic cancer, lung cancer, and cancer in
some unknown location. One patient had no cancer. The total number
of cases so excluded was 80 (16.6%). The final analysis was limited to
402 type I and II adenocarcinomas at the EG junction according to
Siewert’s topographic classification (Siewert et al. 1987). Of the 402
patients (mean age 68.3, range 35-93), males numbered 282 (mean age
66.1, range 35-93), and females 120 (73.5 years, 36-93).
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STUDY V
Patients were identified in the hospital discharge registry records.
Between January 1990 and December 1998, 52 patients with esophageal
or esophagogastric adenocarcinomas underwent palliative treatment
due to advanced stage of the disease or high surgical risk; 40 patients
had histologically confirmed adenocarcinoma at the distal esophagus
and 12 at the gastric cardia. The primary palliative therapy was laser in
32 patients (mean age 73.3 years, range 48-91) and stent in 20 (mean
age 70.1, range 52-87). All patients were new referrals with no previous
intervention or therapy. In addition to endoscopic treatment, 16, 6
after stent placement (30%) and 10 after laser therapy (31%), received
chemotherapy (1), radiotherapy (13), or both (2), based on decisions
made at the interdisciplinary meetings.
7.2 Methods
EPIDEMIOLOGICAL ANALYSIS
Incidence rates were standardized for age to the world standard
population and expressed per 100 000 person-years. Trends in incidence
rates were evaluated annually and for 5-year calendar periods during
1976 to 1995.
TISSUE-SAMPLE COLLECTION
All samples were taken either at endoscopy, with biopsy forceps, or
during surgery, from the resected specimen. In Study II, patients were
told to avoid any acid-suppressive treatment (proton pump inhibitors,
H2-blockers, or all others) for 2 weeks before the sampling. In the
control group, samples were taken 5 cm above the esophagogastric
junction. These were immediately frozen and stored at -70 oC (II). In
Study III, the surgical specimens were processed on the day of collection.
ANALYSIS OF SUPEROXIDE DISMUTASE AND MYELOPEROXIDASE ACTIVITIES AND OF
GLUTATHIONE CONTENT
Myeloperoxidase (MP) activity was determined by modification of a
previous method of Suzuki in which the enzyme catalyzes the oxidation
of 3,3',5,5'-tetramethylbenzidine by H2O2 to yield a blue chromogen
with a maximum wavelength of 655 nm (Suzuki 1983). MP activity is
expressed as units/milligram protein (U/mg protein).
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Superoxide dismutase (SOD) activity was determined by the method
reported by Laihia in which the xanthine/xanthine oxidase-dependent
chemiluminescence was enhanced by both lucinogenin and linoleate
(Laihia 1993). SOD activity is also expressed as U/mg protein.
Glutathione (GSH) content was estimated by Saville’s method
(Saville 1985). GSH concentrations are expressed as nmol/mg protein.
DNA ADDUCT ANALYSIS
The 32P-postlabeling technique was used to analyze total aromatic DNA
adducts. Tissue samples frozen in liquid nitrogen were homogenized in a
Mikro-Dismembrator (Braun, Melsugen, Germany). DNA isolation was
performed essentially as described by Gupta (1984). DNA was digested
enzymatically to 3’-mononucleotides as described (Hemminki et al.
1995). First, DNA was incubated for 2 h at 37 °C with micrococcal
nuclease, then for 2 h at 37 °C with spleen phosphodiesterase in added
20 mM ammonium acetate, pH 5.0. Pi nuclease was used to de-
phosphorylate the normal nucleotides. The modified nucleotides were
converted to 32-P-postlabeled diphosphates in a mixture containing T4
polynucleotide kinase and ATP. TLC analysis was carried out on PEI-
cellulose TLC plates (Macherey-Nagel, Duren, Germany) (Hemminki et
al. 1995). The adducts were detected in a Bio-Rad Image Analysis
System (Bio-Rad Laboratories, Hercules, CA, USA). The average levels
of DNA adducts are expressed as adducts/109 nucleotides. The limit of
sensitivity of the assay is 1/1010.
IMMUNOHISTOCHEMISTRY AND QUANTIFICATION OF BLOOD VESSELS
Five- to ten-µm thick, paraformaldehyde-fixed paraffin-embedded tissue
sections of resection specimens were stained with hematoxylin-eosin
(Sigma, St Louis, MO, USA) and alcian blue 8GX, pH 2.5 (BDH
Laboratory supplies pool, UK) -neutral red (Sigma) to assess tissue
histology, and to localize Barrett’s epithelium-specific goblet cells, and
blood vessels. To quantify blood vessels densities, paraffin-embedded
sections were deparaffined and treated with 0.3% H2O2 in phosphate-
buffered saline-1% Tween (PBS-T; ICN Biomedicall Inc, Aurora, OH,
USA) for 30 min, trypsinized with 0.1% trypsin in 0.1% CaCl2 for 10
min, washed three times with PBS-T, blocked with 1.5% goat normal
serum (Vector Laboratories, Burlingame, CA, USA)-1% bovine serum
albumin (Sigma) in PBS-T for 20 min, incubated with monoclonal
antibody EN4 (anti-CD31, Monosan, Uden, the Netherlands) for 60
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min, washed three times with PBS-T, incubated with secondary
biotinylated goat anti-mouse Ab (Vector) for 30 min, washed three
times with PBS-T, and detected with the ABC-kit (Vector). Thereafter,
cell nuclei were counterstained with hematoxylin. Blood vessels stained
positive for human endothelium were quantified in 200X magnification
microscopic fields (Olympus BX, Tokyo, Japan) and average counts of
nine fields rich in vasculature from the mucosa as well as from the
periphery of the submucosal tissue were determined. The mean score
value and standard deviation were calculated for each specimen.
WHOLE MOUNTS
For three-dimensional studies, a whole-mount method was adapted
from Ryan et al (1998). One- to two-mm thick whole-mount sections
were fixed with Carnoy’s fixative (absolute ethanol:chloroform:acetic
acid; 6:3:1) at room temperature for 1h. Endogenous peroxidase activity
was blocked by incubation in 5% H2O2 in methanol. After being blocked
for 1h with 3% instant skim milk and 0.1% Triton X-100 (Sigma-Aldrich,
Munich, Germany) in PBS (PBS-MT), the sections were stained for
endothelium-specific markers (PAL-E and EN4), angiogenic growth
factors (VEGF)-A and VEGF-C, angiogenic VEGF receptors (VEGFR)-1,
VEGFR-2 and VEGFR-3, matrix metalloproteinases (MMP)-2 and MMP-
9, and smooth muscle cell actin (SMA). The primary antibodies diluted
in PBS-MT (15 µg/ml) were incubated overnight at 4 oC. PAL-E (which
recognizes an undefined endothelial antigen present in microvessels,
but not in arteries) and EN4 (recognizes the endothelium-specific
transmembrane protein CD31 that is expressed both in vascular and
lymphatic endothelium) were purchased from Monosan (Immuno-
diagnostics, Hämeenlinna, Finland). The polyclonal antibodies against
VEGF-A, VEGF-C, VEGFR1-3, MMP-2, and MMP-9 were all from
Santa Cruz Biotechnology Inc, CA, USA. The following day, the sections
were washed five times in PBS-MT for 1h, and thereafter they were
incubated overnight at 4 oC with horseradish peroxidase (HRP)-
conjugated secondary antibodies (DAKO, Copenhagen, Denmark, or
Vector) diluted in PBS-MT (1:200). The sections were washed five
times in PBS-MT for 1h, and color was developed with 0.3 mg/ml
diaminobentzidine (DAB substrate kit; Vector) and 0.03% H2O2. HRP-
conjugated smooth muscle actin monoclonal antibodies were from
DAKO. Whole mount sections were viewed and photographed at 10x
magnification (Leica MZFLIII microscope, Solms, Germany).
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CLINICAL DATA ACQUISITION
In Study IV, the medical records of all patients were retrieved from 23
health-care units, including two private hospitals. The following items
were recorded: patient age and sex, date of diagnosis and treatment,
type and place of primary treatment, type of operation and possible
neoadjuvant or adjuvant therapies, fatal postoperative complications,
disease status at last follow-up contact, and date and cause of death.
Death certificates of those patients undergoing surgery and dying
outside the treatment unit came from the Finnish Central Statistical
Office. Median length of follow-up for surgical patients was 8.0 years
(3.7-12.6). The outcome of patients in the various treatment groups
was analyzed.
Data for Study V were collected from the patient records of
Helsinki and Tampere University Hospitals. Patient demographics and
data on endoscopic procedures and on pre- and post-treatreatment
dysphagia plus follow-up data were registered. All patients were
followed from presentation to death.
ESOPHAGEAL RESECTIONS
Survival of patients who underwent 2-field lymphadenectomy (n=42)
was compared to survival after other less extensive dissections done
through a transthoracic, transabdominal, or transhiatal approach
(n=129). Standard transthoracic esophagectomy generally included
only the removal of the esophagus without lymph nodes. In the
transhiatal technique, the patient underwent esophagectomy by blunt
dissection through the esophageal hiatus and thoracic inlet. In
transabdominal surgery, extended gastrectomy was performed with
esophageal resection as proximal as possible.
Our conventional 2-field lymphadenectomy included en-bloc
esophagectomy with removal of adjacent lymphatic and areolar tissue
between the tracheal bifurcation and the superior border of the
pancreas. The block of tissue removed included, along with the
bronchial, subcarinal, paraesophageal, parahiatal, celiac, left gastric,
and splenic artery lymph nodes, a rim of the diaphragmatic muscle
around the hiatus, the thoracic duct, both the right and left mediastinal
pleura, and the lesser curve of the stomach with a 10 cm distal
resection margin. The dissection was bounded anteriorly by the main
bronchi and pericardium, and posteriorly by the vertebral column and
aorta.
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ENDOSCOPIC TREATMENT MODALITIES
All endoscopic treatments were performed under deep sedation
conducted by an anesthesiologist. A standard fluoroscopically guided
insertion technique with guidewire and radio-opaque markers was used
to insert self-expanding metallic stents. Laser power was supplied by an
Nd:YAG laser (Surgical Laser Technologies, Malvern, USA) via an Olympus
(Tokyo, Japan) endoscope with power settings of 13 watts normally
used. Tumor tissue was treated under direct vision by a contact technique.
Most patients were scheduled routinely for a repeat laser treatment one
to two months after initial therapy. Esophagography with water-soluble
contrast material was done routinely after stent application and after
laser therapy. In the absence of any signs of perforation, patients were
first allowed only fluids orally. Subsequently, every patient received
dietary advice. Swallowing ability was graded clinically before and after
treatment: 0, swallows normally; 1, able to swallow some solid food; 2,
able to eat semisolids only; 3, able to swallow fluids only; and 4,
complete dysphagia (Nicholson et al. 1999).
COST ANALYSIS
To compare total costs of the different palliative therapies, the following
resource information was collected in detail: days spent in hospital,
time in the endoscopic theatre, total number of various interventions,
and retail costs of stents. Cost analysis was performed by summing up
the cumulative costs for each individual over his or her remaining life-
span. Costs are expressed as physical units (time, number) and in
financial terms. Two assumptions were made: First, initial diagnostic
procedures between the groups were similar. Secondly, these patients
used the same community health care resources, whatever the palliative
treatment. These costs were therefore not included in the analysis. In
addition, because differences in survival between those undergoing
the two palliative therapies would influence total costs for these
treatment modalities, costs were expressed as total cost as well as cost
per day of remaining life. Costs in financial terms were expressed as the
current purchase cost of a specific stent (760-1420 EUR) and unit
costs according to estimations of the hospital finance department.
One day as an inpatient was estimated to cost 235 EUR. Cost for
placement of SEMS was estimated as 264 EUR, versus 505 EUR for
laser therapy. The unit costs for these endoscopic procedures included
the cost of staff, materials, medication, and equipment.
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7.3 Statistical analysis
Statistical calculations were carried out with SAS software (Studies II,
V) and with Basic and Advanced model modules of SPSS software
(Studies I, IV). The conventional level of 5% was considered statistically
significant. The following tests were used:
Study I Poisson and linear regression techniques
Study II Non-parametric Kruskal-Wallis test, Wilcoxon rank sum
test, Spearman’s correlation coefficient
Study IV Chi-square test, Kaplan-Meier method, Log-rank test
Study V Mann-Whitney test, Fisher’s exact test, Pearson’s χ2
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8 RESULTS
8.1 Incidence of adenocarcinoma of the esophagus and
cardia in Finland between 1976 and 1995
The incidence of esophageal adenocarcinoma in Finland increased
significantly only in men (Figure 4) with the average annual rate of
increase being 8.8% (95% CI: 5.9 to 14.7%). The total increase in the
age-adjusted incidence rate was almost 300% during the 20-year-long
period, from 0.28 to 0.77 per 105. By 1995, adenocarcinoma accounted
for 27% of all esophageal malignancies among men. In neither sex was
any change evident in the age-adjusted incidence of cancer of the
gastric cardia, remaining around 2.1 per 105 in men, and around 0.5
per 105 in women.
FIGURE 4 Age-adjusted incidence rates of esophageal adenocarcinoma in
Finland, 1976-1995, by gender ( male,  female)
During 1990 to 1995, the combined incidence rate for esophageal
adenocarcinoma and cancer of the gastric cardia was 2.9 per 105 in
men and 0.6 per 105 in women (Figure 5). The increase in this combined
incidence rate in men was only slight, and no change occurred in
women (Figure 5).
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FIGURE 5 Age-adjusted incidence rates of combined esophageal
adenocarcinoma and cancer of gastric cardia in Finland, 1976-1995, by
gender ( male,  female)
8.2 Oxidative stress in malignant transformation of Barrett’s
epithelium
Figures for the determination of myeloperoxidase and superoxide
dismutase activity, glutathione content, and DNA adduct levels are
shown in Table 4. In the GERD-esophagitis-metaplasia-dysplasia-
adenocarcinoma sequence, glutathione content was progressively lower,
and myeloperoxidase activity higher than in controls, but plateauing at
Barrett’s epithelium without dysplasia. Only in Barrett’s mucosa with
dysplasia did SOD activity differ significantly from that of the controls.
In addition, SOD activity was significantly higher in Barrett’s epithelium
without and with dysplasia than in GERD without esophagitis. At the
same time, mean DNA adduct levels were significantly higher than
those of the control group in all five patient groups. Though the levels
between these groups did not differ significantly, the level was highest
in Barrett’s epithelium without dysplasia, and progressively lower in
Barrett’s with dysplasia and with adenocarcinoma.
In the pooled data, Spearman’s correlation analyses between GSH
contents and DNA adducts showed a negative correlation (-0.28,
p<0.05). No correlation existed between SOD or MP activity and DNA
adduct levels.
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8.3 Angiogenesis and lymphangiogenesis in Barrett’s
epithelium and in esophageal adenocarcinoma
Barrett’s salmon-pink mucosa was characterized by intense infiltration
of endothelium-specific protein CD31-positive angiogenic blood vessels
(Figure 6D). Microvessel density was doubled (±SD) in Barrett’s
epithelium (83.0±61.3) and was two- to three-fold in advanced
adenocarcinoma (112.5±46.3) above that of normal esophageal
mucosa (39.4±22.9), the number of capillaries remaining unchanged.
The whole-mount technique showed that only a few blood vessels
penetrated into normal esophageal mucosa (Figures 6A and 7A). In
Barrett’s epithelium, and in related dysplasia and adenocarcinoma,
new angiogenic microvessels infiltrated the entire mucosa (Figures 6B,
and 7B-D). The angioarchitecture within Barrett’s epithelium consisted
of new microvessels that were very small and deformed, containing
tortuosities, corkscrew structures, blind ends, and abnormal branching
(Figure 6B).
Barrett’s epithelium overexpressed vascular endothelial growth
factor A and its receptor, VEGFR-2. The new blood vessels expressed
the matrix metalloproteinases MMP-2 and MMP-9 on their exterior
surfaces. In paraffin sections, an increasing percentage of vessels were
devoid of smooth muscle actin in Barrett’s epithelium (5%), dysplasia
(25%), and adenocarcinoma (40%).
Lymphangiogenic growth factor VEGF-C was not expressed in
normal esophageal mucosa, but its increased expression during the
progression of Barrett’s epithelium to dysplasia and to adenocarcinoma
was evident. In parallel, expression of lymphangiogenic receptor VEGFR-
3 was upregulated, particularly in dysplasia and adenocarcinoma
(Figures 7E and F). The lymphatics of normal and metaplastic tissue
were compact; in dysplasia and adenocacinoma they were more loose
in structure (Figures 7E and F). The metastatic lymph nodes were
positive for both VEGF-C and VEGFR-3 expression.
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FIGURE 6 Barrett’s epithelium is neovascularized. Whole mount (A and B) and paraffin
sections (C and D) from normal esophagus and Barrett’s epithelium were stained with
antibodies against the undefined vascular endothelial marker PAL-E (A and B) or
hematoxylin and EN4 (C and D). Endothelium-specific markers, monoclonal antibodies
EN4 and PAL-E, stain capillaries and microvessels in both mucosa (M) and submucosa
(SM). The blood-vessel architecture of normal esophagus (A) is distorted by new netlike
blood vessel ingrowth in Barrett’s epithelium (B). Note the strong increase in density of
new blood vessels penetrating mucosa adjacent to Barrett’s epithelium (arrow in panel
D) in comparison to that of normal esophageal mucosa (C); also note equal thickness
of mucosa layers. Scale bars: 20 µm, A and B; 50 µm, C and D.
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FIGURE 7 Whole-mount sections showing metaplasia-dysplasia-adenocarcinoma
sequence in Barrett’s esophagus stained with EN4 antibody staining both blood vessels
and lymphatic vessels (A-D), or stained with anti-VEGFR-3 (E-F). The pre-existing
vascular bed in submucosa and some blood vessels nourishing the mucosa are clearly
visible in normal esophageal mucosa (A; arrow), whereas in Barrett’s epithelium (B;
arrow), dysplasia (C; arrow), and adenocarcinoma (D; arrow), the vascular bed
infiltrates the whole mucosa. Anti-VEGFR-3 stains fewer vessels (E and F) than does
EN4 (A-D), and VEGFR-3-positive lymphatic vessels (E and F) are morphologically
distinct from blood vessels (D; see also Figs. 6A and 6B). E and F show the appearance
of lymphatic vessels in dysplasia (E) and adenocarcinoma (F); panel F shows invasion of
lymphatic vessel into adenocarcinoma tumor stroma, as well.
Scale bars: 20 µm, A-F.
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8.4 Treatment and outcome of patients with adenocarcinoma
of the esophagus and esophagogastric junction
Of the 402 patients, 171 patients underwent resection, and 19,
explorative surgery (Table 5), making the resectability rate of these
patients 171 of 190 (90.0%). Of the remaining 212, 136 were treated
palliatively, mainly with endoscopic treatment modalities, and 76
received no treatment because of advanced stage, poor general physical
condition, or both (Table 5).
TABLE 5 Primary treatment for adenocarcinoma of esophagus and cardia
Treatment modality
Surgical approach 171 (42.5%)
Transthoracic 104
Transhiatal 21
Transabdominal 46
Explorative operation 19 (4.7%)
Only exploration 7
+ stent +radio- and/or chemotherapy 6
+ stent 3
+ laser 1
+ gastrostomy 1
+ chemotherapy 1
Palliation 136 (33.8%)
Laser 54
Laser + chemo- and/or radiotherapy 13
Laser + brachytherapy 1
Stent 34
Stent + chemo- and/or radiotherapy 6
Dilation 5
Brachytherapy 1
Chemo- and/or radiotherapy 14
Jejunostomy/gastrostomy 6
Percutaneus endoscopic gastrostomy 1
Endoscopic excision 1
No treatment 76 (18.9%)
Total 402
Overall, 5-year survival for patients with adenocarcinoma near the
esophagogastric junction was 12.5%. Patients without treatment
(median survival 36.5 days, range 0 days-68.1 months), with palliation
(median survival 116.5 days, range 0 days-59.5 months), or with
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exploratory surgery (median survival 211 days, range 113 days-26.6
months) had a dismal prognosis (Figure 8). Altogether, only one of
231 survived 5 years, making the rate less than one percent. After
resection, median survival was 17.6 months (0-101.1), and the Kaplan-
Meier estimate of survival at 5 years was 29.0%. However, the 5-year
survival rate was significantly better in patients with 2-field
lymphadenectomy (n=42) than in patients with less extensive surgery
(n=129), when all deaths (50.0% vs. 23.2%, p=0.005) or only cancer
deaths (55.0% vs. 28.2%, p=0.0036) were included.
FIGURE 8 Five-year survival of 402 patients with adenocarcinoma of the
distal esophagus and at the GE junction according to treatment method
(resection —, explorative surgery - - -, palliation —, no treatment —)
Among the 171 patients who underwent resection, 15 (8.8%) died
within 30 days and 31 (18.1%) within 90 days, with the main causes of
death not differing between these two groups (Table 6). One of these
patients died because of disease-related general weakness within 30
days and four of these from disease progress within 90 days. No
statistically significant difference appeared between conventional 2-
field lymphadenectomy and less invasive procedures in 30-day (7.1%
vs. 9.3%) and in 90-day (11.9% vs. 20.2%) surgical mortality.
In follow-up, 13 of 123 (10.6%) patients operated on died without
evidence of disease recurrence (Table 7), but overall, 341 of 354
(96.3%) of those not surviving died of their disease.
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TABLE 6 Cause of death in patients dying within 30 and 90 days
postoperatively
Complication 30 days 31-90 days Total
Myocardial infarction 4 2 6
Cardiomyopathia and heart insufficiency - 1 1
Cerebrovascular accident 1 1 2
Colon conduit necrosis / perforation 1 1 2
Anastomotic leak + sepsis - 1 1
Liver failure 1 - 1
Pancreatitis 1 1 2
Colon perforation 1 - 1
Pneumonia 4 2 6
Aspiration/Pneumonia +ARDS 1 2 3
Lung embolism - 1 1
Disease (General weakness) 1 4 5
Total (%) 15 (8.8) 16 (9.4) 31 (18.1)
TABLE 7 Cause of late death (>90 days) in surgical patients (n=123) without
evidence of disease recurrence
Cause N=13
(10.6%)
Pneumonia 3
Lung cancer 2
Chronic obstructive lung disease 1
Myocardial infarction 1
Cerebral infarction 1
Thoracic aortic aneurysm 1
Rectal cancer 1
Breast cancer 1
Alcohol liver damage 1
Intoxication 1
8.5 Outcome and costs of laser coagulation and
self-expanding metallic stents
The technical success rate for the stent group was 18 of 20 (90%) and
for laser therapy was 30 of 32 (94%). In two patients, SEMS were
incorrectly inserted. Two unsuccessful laser therapies caused one fatal
perforation and one total esophageal obstruction. The magnitude of
improvement in dysphagia between the study groups did not differ
(Table 8).
Patients in the stent group experienced significantly more (p=0.043)
complications than did those in the laser group (Table 8). Hospital
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mortality was also higher in the stent group (4 vs. 1; 20% vs. 3.1%,
p=0.066). The only death caused by laser therapy was due to perforation.
Causes of death after stent placement were due to pneumonia, sepsis,
intestinal ischemia, and aspiration. The rate of long-term complications
did not differ between groups, nor was there any significant difference in
inter-group survival (p=0.225) (Table 8).
TABLE 8 Outcome of endoscopic treatment for 52 patients
Treatment modality Laser (n=32) Stent (n=20)
Technical success (%) 94 90
Median post-treatment dysphagia score (range) 2 (0-4) 2 (2-4)
Median improvement in dysphagia score (range) 1 (-1-3) 1 (-2-2)
Early complications (%) 6.3 30*
Late complications (%) 41 30
Hospital mortality (%) 3.1 20
30-day mortality (%) 3.1 40†
Survival (days) (means ± SD) 144 ± 138 139 ± 158
*P=0.043 and †p=0.0011 in comparison with laser therapy
Costs by group can be expressed as physical units and in financial
terms (Table 9). The number of interventions was significantly higher
(p=0.0048) for laser therapy than for the stent group. The total
amount of time required by endoscopies was 118 min (10 min-12.6
hours) for the laser group and 38 min (10-100 min) for the stent group
(p=0.0048). No difference existed between the groups in time spent in
hospital (p=0.370). Overall costs and cost per day of palliation did not
differ significantly between the expansible stent group (respectively,
5360 EUR, range 1820-14590; 175 EUR, range 5-620) and the laser
therapy group (5450 EUR, range 1110-31775; 85 EUR, range 6-1175
EUR).
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TABLE 9 Costs (means ± SD) by group, expressed as physical units and in financial
terms (in EUROS).
Treatment modality Laser (n=32) Stent (n=20)
No. of interventions 3.4 ± 4.0 1.9 ± 1.6*
No. of stents 0.5 ± 0.6 1.4 ± 0.5†
No. of laser treatments 2.6 ± 3.6 0.05 ± 0.2†
No. of endoscopies 0.2 ± 0.37 0.3 ± 0.73
Other interventions/admissions 0.2 ± 0.49 0.3 ± 0.47
Days spent in hospital 15.1 ± 14.8 12.9 ± 11.5
Time spent in endoscopic theatre (min) 118 ± 152 38 ± 25*
Stent costs 470 ± 715 1705 ± 695†
Procedure costs 1530 ± 1800 620 ±610‡
In-patient costs 3460 ± 3505 3040 ± 2720
Total costs 5450 ± 5500 5360 ± 3650
Cost per day of survival 85 ± 205 175 ± 205
*P=0.0048, †p<0.0001, and ‡p=0.0002 in comparison with laser therapy
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9 DISCUSSION
9.1 Reliability of data
Studies based on registry data can be no better than data provided by
the original sources. Several epidemiological studies of esophageal
adenocarcinoma have omitted cancer of the gastric cardia (Yang and
Davis 1988, Hesketh et al. 1989, Hansson et al. 1993, McKinney et al.
1995). In addition, data have been based on relatively small populations
(Levi 1991, Pera et al. 1993), or completeness of records has been less
than 90% (Armstrong and Borman 1996). Both the quality of the data
and the level of quality control of the Finnish Cancer Registry have
been well evaluated (Teppo et al. 1994). Coverage of the Registry for
solid tumors is excellent (>99%). Completeness of the data should
thus cause no bias in Studies I and IV. Moreover, we must assume no
subtype bias among histologically verified cases (I). At the Finnish
Cancer Registry, one and the same pathologist evaluated all the
histologically problematic cases throughout the entire study period.
9.2 Epidemiology of adenocarcinoma near the
esophagogastric junction
This study shows a significant increase with time in the incidence of
esophageal adenocarcinoma in Finnish men. At the same time, incidence
of esophageal adenocarcinoma in women and cancer of the gastric
cardia in both sexes have remained relatively stable. This is also the
trend in several other countries such as Australia, New Zealand, Norway,
Scotland, Sweden, and Switzerland (Levi et al. 1990, Levi 1991, Hansson
et al. 1993, McKinney et al. 1995, Armstrong and Borman 1996,
Hansen et al. 1997, Lord et al. 1998). In some countries (USA and
England), esophageal adenocarcinoma in women and cancer of the
gastric cardia in both genders are both on the increase, as well (Blot et
al. 1991, Dolan et al. 1999).
At one time, adenocarcinomas close to the EG junction were
classified as being of gastric origin. With heightened awareness of
esophageal adenocarcinoma, change in incidence may reflect a change
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in these tumors’ classification. For example, the study by Webb and
Busuttil (1978) included 52 adenocarcinomas of the esophagus and
esophagogastric junction. Of these, 22 had hiatal hernias with a mean
upper tumor level at 31 cm in the esophagus. Only two of these were
classified as primary esophageal adenocarcinomas. Thus, a substantial
degree of misclassification has taken place. Evaluation of the incidence
rates of esophageal adenocarcinoma becomes even more vulnerable
to error when the clinical difficulties in establishing the exact origin of
a tumor at the EG junction and the ambiguous definition of the gastric
cardia in the literature are included.
The problem of distinguishing distal esophageal adenocarcinoma
from cancer of the gastric cardia could be further magnified by the
difficulty in separating cardia tumors from non-cardia gastric cancer.
The increasing incidence of cardia cancer can be explained by the
misclassification of gastric tumors (Ekström et al. 1999). Based on the
present Study (I), the incidence of cardia cancer in Finland has remained
unchanged. In Study IV, of 482 adenocarcinomas near the EG junction,
73 (15.1%) had, however, to be excluded from the study due to their
subcardial location (Siewert type III). In addition, gastric cardia and
non-cardia cancers have been far more common than esophageal
adenocarcinoma. Thus, a proportionally small degree of misclassification
of these tumors to a more oral location would cause a substantial rise in
the incidence of esophageal adenocarcinoma.
If the combined rates of esophageal and gastric cardia adeno-
carcinomas were calculated, incidence rates would not change, or at
least the increase in several countries would seem more reasonable
(Hansen et al. 1997, Lord et al. 1998, Blot et al. 1991, Armstrong and
Borman 1996, Levi 1991, Levi et al. 1990). In Finland, these combined
incidence rates have also risen steadily, but not dramatically. Therefore,
to get a truthful picture of changes in the occurrence of these cancers,
when incidences of distal esophageal adenocarcinoma are reported,
the focus should be on all the adenocarcinomas near the EG junction.
9.3 Why is the incidence of adenocarcinoma increasing?
The reason for the continuous rise in the incidence of adenocarcinoma
near the EG junction is unknown. Little evidence exists to show that the
prevalence of Barrett’s metaplasia, the most important risk factor for
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esophageal adenocarcinoma, has increased over time (Watson et al.
1999). Nor do consistent data exist on the changing prevalence of
GERD.
Four recent studies have revealed a modestly increased risk for
esophageal and gastric cardia adenocarcinoma in smokers (Kabat et
al. 1993, Vaughan et al. 1995, Zhang et al. 1996, Gammon et al.
1997). It seems that smoking cannot explain the recent rise in incidence
of adenocarcinoma near the EG junction, because prevalence of
cigarette smoking is decreasing simultaneously with the increase in
cancer rate (Pierce et al. 1989). The risk for adenocarcinoma of the
esophagus and gastric cardia persists, however, for nearly 30 years
after cessation of smoking (Gammon et al. 1997). In addition, that
group suggests that in these cancers cigarette carcinogens act in an
early stage of carcinogenesis. The pattern of smoking prevalence during
the 20th century (increasing up to the 1970’s) may thus contribute to
recent changes in incidence of adenocarcinoma in the esophagus and
gastric cardia (Pierce et al. 1989).
The contribution of alcohol to the increasing incidence of adeno-
carcinoma of the esophagus and gastric cardia is most likely to be
minimal. Recent epidemiological studies demonstrate only a weak or no
association between alcohol consumption and these adenocarcinomas
(Vaughan et al. 1995, Zhang et al. 1996, Gammon et al. 1997).
Obesity seems to be a risk factor for esophageal adenocarcinoma
and also for cancer of the gastric cardia (Brown et al. 1995, Vaughan
et al. 1995, Chow et al. 1998a, Lagergren et al. 1999b). The growing
prevalence of obesity in Western countries and the rising rates of
esophageal adenocarcinoma are parallel phenomena. Possibly by
causing increased gastroesophageal reflux, obesity may be of more
and more importance as an indirect risk factor for this disease.
It is also estimated that 10% of the esophageal adenocarcinomas
may be attributable to the use of LES-relaxing drugs (Lagergren et al.
2000). Our study did not, however, seek any association between
these drugs or other potential risk factors and the rising incidence of
adenocarcinoma near the EG junction.
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9.4 Pathogenesis of esophageal adenocarcinoma
Simultaneous formation of DNA adducts, increased oxidative stress
(increased MP activity), and decreased antioxidant capacity (reduced
GSH content) in the esophagitis-metaplasia-dysplasia-adenocarcinoma
sequence of Barrett’s esophagus indicates the important role in the
pathogenesis and malignant transformation of Barrett’s epithelium
played by oxidative stress. At the same time, this sequence was
characterized by an increased frequency of highly abnormal micro-
vessels, an increasing percentage of immature vessels, and an increased
expression of VEGF-A and VEGF-C.
Gastroesophageal reflux disease has been shown to increase the
production of oxygen free radicals in the esophageal mucosa in studies
measuring free radicals by means of chemiluminescence assay and
either lipid peroxidation or myeloperoxidase activity in patients with
reflux esophagitis or Barrett’s epithelium (Wetscher et al. 1995, Olyaee
et al. 1995). In rats, reflux-related esophageal mucosal damage and
lipid peroxidation may be reduced by antioxidants (Oh et al. 2001).
Our study supports these findings, and in addition, in the present
study, the increase in DNA adducts simultaneously with oxidative
stress in complicated GERD strengthens the role of gastroesophageal
reflux in the pathogenesis of esophageal adenocarcinoma. Though the
size of the present study is limited, it appears to establish direct
evidence to link oxidative stress with esophageal adenocarcinoma. An
epidemiological association between higher intake of antioxidants and
decreased risk for esophageal adenocarcinoma exists, as well (Terry et
al. 2000). Oxidative stress can therefore be considered one of the
important driving forces for carcinogenesis in gastroesophageal reflux
disease and in Barrett’s epithelium.
Some carcinogens may enhance endogenous DNA adduct formation
by an indirect mechanism such as induction of oxidative stress (Nestmann
et al. 1996). The efficiency of the local metabolism will also affect
exogenous DNA adduct formation, because a large proportion of
genotoxic agents require activation to electrophilic compounds (De
Flora et al. 1996). The step-by-step increase seen in MP activity indicates
increased oxidative stress related to the severity of reflux disease. In
addition to amplified oxidative stress, activation of carcinogens by MP is
a possible mechanism resulting in DNA adduct formation, tissue injury,
and carcinogenesis (Petruska et al. 1992, Williams 2001). In mice, MP
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has transformed a respiratory carcinogen to an ultimate carcinogenic
metabolite, and furthermore, has enhanced DNA adduct formation
(Petruska et al. 1992).
In our study, MP activity and DNA adducts were highest in Barrett’s
esophagus rather than in adenocarcinoma. The cause of this depleted
MP activity in adenocarcinoma is unclear. In tumor stenosis it may
reflect decreased gastroesophageal reflux-related oxidative stress and
inflammation, and therefore a dose-response relationship between
the level of adducts and oxidative stress. Previously, etheno-DNA
adduct levels were found to be lower in carcinoma than in pre-
neoplastic colonic polyps (Schmid et al. 2000). Similarly, in tumor
tissues, DNA adduct levels were lower than in tumor-adjacent tissue
(Wang et al. 1998). These findings were in close agreement with our
data. As a result, the level of DNA adducts seems to be higher during
carcinogenesis and not in the final stage of cancer. Though DNA
adducts play a role in risk for cancer induction and progression, the
long latency period of cancer development may lead to the loss of
DNA adducts as a consequence of accumulation of multiple genetic
abnormalities in genes and on chromosomes (Nestmann et al. 1996,
Winjnhoven et al. 2001).
In the present study, DNA adducts were already higher and GSH
levels lower in GERD without esophagitis than in controls, indicating
the early role of oxidative stress in reflux-related esophageal mucosal
damage. With further suppression of antioxidant capacity (GSH), and
with increased MP activity in esophagitis and in Barrett’s epithelium,
mucosa is exposed to amplified oxidative stress; a low content of GSH
in Barrett’s epithelium has indeed been observed (Peters et al. 1993).
In an experimental reflux model involving ligation of the proximal
jejunum in rats, mucosal decrement of glutathione was discovered in
esophagitis (Oh et al. 2001). In that rat model, antioxidants attenuated
the depletion in GSH levels. The present study shows a negative
correlation between GSH content and DNA adduct formation,
indicating that the low antioxidant capacity of the esophageal mucosa
in Barrett’s esophagus elevates DNA adduct formation and the risk for
carcinogenesis. Hence, reflux-related oxidative stress seems to deplete
GSH and enhance cellular sensitivity to various agents. In GERD, the
lower GSH content may, however, be due as well to the impairment of
the glutathione redox capacity, which occurs in cultured endothelial
cells at an acidic pH (Ikebuchi et al. 1996).
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Endothelial cell proliferation and microvascular remodeling occur
at an early stage in chronic inflammation (Ezaki et al. 2001), enabling
metabolic support for the tissues and allowing inflammatory cells to
reach the diseased area. These cells release angiogenesis activators
such as VEGF, angiopoietin 1, FGF, and TGF, among many others, in
abundance (Carmeliet and Jain 2000). Several of these potential
proangiogenic factors, such as MMP, VEGF, TGF, and FGF, have been
discovered in the metaplasia-dysplasia-adenocarcinoma sequence of
Barrett’s esophagus (Triadafilopoulo and Kumble 1996, Soslow et al.
1997, Salmela et al. 2001). In our study, high expression of vascular
endothelial growth factor and its receptor, and of matrix metallo-
proteinases suggests their importance in angiogenesis in Barrett’s
epithelium and related adenocarcinoma. These results, taken together,
suggest an interesting functional interplay between angiogenic cells and
new invading blood vessels in neovascularization of Barrett’s mucosa.
Accelerated angiogenesis, assessed by higher microvessel density in
microscopic fields, has been discovered in Barrett’s epithelium and
esophageal adenocarcinoma (Torres et al. 1999, Millikan et al. 2000,
Couvelard et al. 2000). In this study, the microvessel density was doubled
in Barrett’s epithelium and was two- to three-fold in advanced adeno-
carcinoma above that in normal esophageal mucosa. Furthermore, the
whole-mount technique provided three-dimensional evidence that during
the early stage of tumor development in Barrett’s epithelium the rich
new vascular bed is already highly abnormal.
In several cancers such as breast and lung cancer, the greater the
degree of angiogenesis detected in a primary tumor, the worse its
prognosis (Toi et al. 1993, Weidner 1995, Yuan et al. 2001). In
Barrett’s carcinoma, a direct relationship between angiogenesis and
metastasis remains to be established (Torres et al. 1999, Millikan et al.
2000). On the other hand, esophageal adenocarcinoma spreads early
into the lymphatic system (Rice et al. 1998, Stein et al. 2000). Because
expression of VEGF-C and its receptor VEGFR-3 in adenocarcinoma
overlapped, it seems that VEGF-C may induce, as suggested in gastric
cancer, proliferation of lymphatic vessels in the stroma of a tumor via
activation of VEGFR-3 (Yonemura et al. 2001). The structure of
lymphatics in dysplasia and cancer was loose, and they were also seen
to penetrate the adenocarcinoma tumor stroma (Study III). It is
reasonable to assume that in these circumstances, lymphatic vessels
offer less resistance and more contact area for penetration of cancer
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cells into the lymphatic system than into blood vessels. Tumor
lymphangiogenesis may therefore be an important phenomenon for
the lymph node metastasis formation which is frequent in esophageal
adenocarcinoma.
9.5 Treatment
To our knowledge, this may be the first study to establish, in one
clearly defined geographical area, and for 9 years, the fate of every
patient undergoing modern treatment for adenocarcinoma at the
distal esophagus and at the EG junction (Study IV). Overall, prognosis
was still poor. Only 12.5% survived longer than 5 years. Operative
resection offered the best chance for a cure with a 5-year survival rate
of 29.0%. Less than one percent of patients treated with other methods
were alive at 5 years. On the other hand, half the adenocarcinoma
patients eligible for major surgery with 2-field lymphadenectomy had a
chance to survive long-term. In advanced disease, these patients were
palliated as effectively with placement of self-expandable metallic
stents as with laser therapy, without differences in overall cost of
therapy (Study V).
The 5-year survival rate after esophagectomy according to Earlam’s
large review was 12% in the 1960’s and 1970’s (Earlam and Cunha-
Melo 1980). Similarly, a population-based analysis revealed an only
9.8% 5-year survival for radical resection of adenocarcinoma at the
gastric cardia (Allum et al. 1980). The 5-year survival rate of 29.0% in
our unselected material was similar to that recently reported by Siewert
et al (32.3%) and Collard (35.3%) (2000; 2001). Overall survival of
these patients has improved during recent decades, reflecting earlier
diagnosis and improvement in the results of surgical therapy. Because
the potentialities of radical surgery for adenocarcinoma near the EG
junction are much greater than 20 or 30 years ago, surgery should be
considered the primary mode of therapy for patients without
contraindications.
Previously, esophagectomy had the highest surgical mortality (29%)
of any routinely performed surgical procedure (Earlam and Cunha-Melo
1980). Similarly, radical resection of adenocarcinoma at the gastric
cardia carried a 19% 30-day mortality (Allum et al. 1980). In a recent
meta-analysis including 50 articles published between 1990 and 1999,
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in-hospital mortality among 7584 patients after esophagectomy was
7.5% (Hulscher et al. 2001). Our study revealed an 8.8% 30-day and an
18.1% 90-day death rate for surgical treatment of adenocarcinoma near
the EG junction.
Centers with large experience have achieved lower mortality rates
(Orringer et al. 1999, Siewert et al. 2000, Collard 2001), and increasing
evidence does show that surgical volume and experience has a major
impact on surgical mortality after major cancer surgery, especially
after esophagectomy (Miller et al. 1997, Begg et al. 1998, Patti et al.
1998, Swisher et al. 2000). In addition to better patient selection and
overall experience, progressive refinement in surgical techniques and
in perioperative care of patients is able to reduce both the morbidity
and mortality after esophagectomy and to improve survival (Sutton et
al. 1998, Whooley et al. 2001).
In surgery for esophageal cancer, the role of radical lympha-
denectomy is a debated topic. No prospective randomized study has
evaluated its role in surgical treatment of adenocarcinoma of the
esophagus and EG junction. The most important concern is whether a
more radical lymph node dissection really contributes to an increase in
survival. Those patients who would potentially benefit from more
extensive resections are those with only a few metastatic lymph nodes
(Nigro et al. 1999). Two recent analyses revealed 5-year survival rates
of 40% and 52% for patients with adenocarcinoma after en-bloc
esophagectomy (Altorki and Skinner 2001, Hagen et al. 2001). In our
population-based series, comparable results (5-year survival 50% vs.
23% after less extensive surgery) were also achieved in patients who
underwent en-bloc esophagectomy in Helsinki and Tampere University
hospitals. Therefore, in centers with considerable experience, such
radical surgery should be favored for patients eligible for major surgery.
Before the 1980’s, the role of oncological therapy was considered
very limited in the treatment of this adenocarcinoma (Earlam and
Cunha-Melo 1980). In the present population-based analysis, only
9.7% of 402 patients received radiation, chemotherapy, or both, alone
or in combination with endoscopic treatment modalities. This is
contrary to a recent hospital-based evaluation revealing that 44% of
patients with adenocarcinoma of the esophagus received primarily
only oncological therapy (Daly et al. 2000). Many of these patients are
in an advanced stage or are in poor physical condition, or both, and
are unable to tolerate treatments with high frequencies of severe side-
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effects (Hejna et al. 1996, Cooper et al. 1999). In advanced disease,
the response rate to chemotherapy or radiochemotherapy has been
between 14% and up to 57% and has lasted only a few months
(Khansur et al. 1994, Highley et al. 1994, Hejna et al. 1996, Enzinger et
al. 1999). Therefore, oncological therapy by itself still plays only a
limited role in the overall treatment of patients with adenocarcinoma
near the EG junction. The role of multimodality therapy is evolving,
with some evidence of neoadjuvant radiochemotherapy improving
survival (Walsh et al. 1996). At this point, however, the role of
preoperative chemoradiotherapy in the treatment of adenocarcinoma
near the EG junction remains unresolved. Before those patients who
benefit from chemoradiotherapy can be clearly identified, others may
still suffer the associated complications. Multimodality treatment
should, therefore, be offered only to patients with locally advanced
tumors with strong suspicion of lymph node metastases.
The role of endoscopic treatment modalities for palliation of
dysphagia and improvement of quality of life are of great importance.
No prospective randomized studies compare laser therapy and self-
expanding metallic stents in the treatment of malignant dysphagia
entirely due to adenocarcinomas near the EG junction. SEMS have
proven superior to esophageal intubation with plastic prostheses
(Knyrim et al. 1993, DePalma et al. 1996, Siersema et al. 1998).
Similarly, laser therapy has provided better palliation than have plastic
prostheses (Alderson and Wright 1990, Carter et al. 1992). Based on
Study V, it seems that laser therapy palliates dysphagia of patients with
adenocarcinoma at the distal esophagus or at the EG junction effectively
without increased costs or hospital stays and with lower morbidity and
mortality rates than for self-expanding metallic stents. Laser therapy is
therefore warranted for patients with advanced adenocarcinoma near
the EG junction with neither a long, tortuous stricture nor extensive
extrinsic compression. Because the treatment, regardless of the primary
method, in many cases has to be changed during the course of the
therapy, these endoscopic treatment modalities should be considered
complementary rather than mutually exclusive.
Regardless of increased awareness of this disease, of improvement
in staging, and of a more radical surgical approach, even today little
can likely be done to improve overall prognosis for the whole population
of patients with adenocarcinoma near the EG junction. Probably the
only means to achieve a better prognosis for the majority is earlier
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diagnosis. On the other hand, management of these tumors is evolving
continuously, with some evidence, for example, that neoadjuvant
radiochemotherapy improves survival (Walsh et al. 1996); only those
patients with a response do, however, benefit from it, and others may
still suffer from its associated complications (Heath et al. 2000,
Liedman et al. 2001, Urba et al. 2001). Study IV clarifies the outcome
to be expected after current treatment modalities in unselected patients
and provides a benchmark against which new therapies can be assessed.
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10 SUMMARY
Adenocarcinoma near the esophagogastric junction has been one of
the most lethal malignancies, with less than 5% of patients surviving in
the long term. In this thesis we studied the epidemiology, pathogenesis,
and treatment of this disease.
The incidence of esophageal adenocarcinoma has increased
significantly in Finland only in men. In men the combined incidence of
adenocarcinomas in the esophagus and gastric cardia has increased
steadily as well, but this increase is not as dramatic as in esophageal
adenocarcinoma.
Simultaneous formation of DNA adducts, increased oxidative
stress, and decreased antioxidant capacity have revealed the important
role played in the pathogenesis and malignant transformation of
Barrett’s epithelium by oxidative stress. This metaplasia-dysplasia-
carcinoma sequence in Barrett’s esophagus was also characterized by
increased density of microvessels, overexpression of VEGF-A and its
receptor, and of MMP-9, and by an increasing percentage of immature
blood vessels. In addition, the whole-mount technique offered three-
dimensional evidence that the morphology of the rich new vascular bed
is already highly abnormal in non-malignant Barrett’s epithelium, and
the structure of the lymphatics in dysplasia and cancer is loose. In these
stages, expression of VEGF-C and VEGFR-3 was upregulated, as well.
Lymphangiogenesis was suggested to be an important phenomenon for
the frequent lymph node metastasis formation.
It seems that for patients having adenocarcinoma at the distal
esophagus or at the esophagogastric junction, laser therapy palliates
dysphagia more effectively without increased costs or hospital stays,
and with lower morbidity and mortality rates than do self-expanding
metallic stents. Overall prognosis in this dreadful disease is still poor,
and only surgical treatment is able to offer a cure. A substantial
percentage of patients eligible for major surgery now achieve long-
term survival.
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11 CONCLUSIONS
I The combined incidence of esophageal and gastric cardial
adenocarcinomas shrinks the substantial rise in the incidence of
esophageal adenocarcinoma in Finnish men to a more reasonable
increase. To obtain an accurate picture of changes in the occurrence
of these adenocarcinomas, the focus should be on all these
adenocarcinomas near the esophagogastric junction, when
incidences of distal esophageal adenocarcinoma are reported.
II Simultaneous formation of DNA adducts, an increased myelo-
peroxidase-related oxidative stress, a decreased antioxidant capacity
(glutathione content) and a negative correlation between glutathione
content and DNA adducts in the GERD-esophagitis-metaplasia-
dysplasia-adenocarcinoma sequence of Barrett’s esophagus appear
to be direct evidence linking oxidative stress to the malignant
transformation of Barrett’s epithelium.
III Barrett’s esophagus is strongly neovascularized. High expression of
vascular endothelial growth factor and its receptor, and matrix
metalloproteinases suggests their important role in angiogenesis in
Barrett’s epithelium and related adenocarcinoma. Furthermore, in
esophageal adenocarcinoma, the tumor lymphangiogenesis may be
an important phenomenon in the frequent lymph node metastasis
formation.
IV The overall prognosis for adenocarcinoma near the EG junction is
poor, but because a substantial percentage of patients eligible for
major surgery achieve long-term survival, a chance for radical
surgery with 2-field lymphadenectomy should be offered to them.
V Based on our results, laser therapy is warranted for patients who
have advanced adenocarcinoma near the EG junction with neither a
long, tortuous stricture nor extensive extrinsic compression. Because
the treatment, regardless of the primary method, in many cases has
to be changed during the course of therapy, these endoscopic
treatment modalities should be considered complementary rather
than mutually exclusive.
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